<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">27873</article-id><article-id pub-id-type="doi">10.7554/eLife.27873</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology and Stem Cells</subject></subj-group><subj-group subj-group-type="heading"><subject>Genomics and Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-86175"><name><surname>Bak</surname><given-names>Rasmus O</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7383-0297</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-87606"><name><surname>Dever</surname><given-names>Daniel P</given-names></name><email>ddever1@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-87607"><name><surname>Reinisch</surname><given-names>Andreas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9333-7689</contrib-id><email>reinisch@stanford.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-87610"><name><surname>Cruz Hernandez</surname><given-names>David</given-names></name><email>dcruzher@stanford.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-63214"><name><surname>Majeti</surname><given-names>Ravindra</given-names></name><email>rmajeti@stanford.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14720"><name><surname>Porteus</surname><given-names>Matthew H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3850-4648</contrib-id><email>mporteus@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pediatrics</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Medicine, Division of Hematology</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Medicine, Institute for Stem Cell Biology and Regenerative Medicine</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Medicine, Cancer Institute</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5101"><name><surname>Levine</surname><given-names>Ross L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Department of Biomedicine, Aarhus University, Aarhus, Denmark</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Aarhus Institute for Advanced Studies (AIAS), Aarhus University, Aarhus, Denmark</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>09</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e27873</elocation-id><history><date date-type="received" iso-8601-date="2017-04-18"><day>18</day><month>04</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-09-26"><day>26</day><month>09</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Bak et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Bak et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-27873-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.27873.001</object-id><p>Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.27873.002</object-id><title>eLife digest</title><p>Our DNA contains thousands of sections called genes that encode the information needed to make all the cells in the human body. To understand what the genes do and how they contribute to diseases, it is crucial for researchers to be able to switch individual genes on or off or make precise changes to the ‘letters’ in their code. Since most genes act in complicated networks it would be very useful to be able to edit several genes at the same time, especially when studying cancer and other diseases that are caused by defects in multiple genes.</p><p>CRISPR/Cas9 is a relatively new technique that allows the code of individual genes to be precisely edited. To edit a gene, CRISPR/Cas9 first breaks the DNA at the site of interest and this break is subsequently repaired using new DNA templates that introduce the desired change in the code. In this way, the letters of the code can be changed with the same precision that one edits the letters and words of a document. This technique has been successfully used to edit the code of single genes, but it is much more difficult to use it to edit several genes at the same time.</p><p>To import new DNA repair templates into human and other mammalian cells, researchers have used harmless virus-like particles called rAAV vectors. Researchers load the DNA templates into rAAV vectors, which are able to enter the cells and carry the templates to the DNA of the cells. Bak, Dever, Reinisch et al. combined CRISPR/Cas9 with rAAV template delivery to precisely edit several genes in human cells, including blood stem cells. In this new system, CRISPR/Cas9 directs the insertion of new pieces of DNA carried by rAAV6 vectors into specific genes.</p><p>The system developed by Bak, Dever, Reinisch et al. allows several genes to be precisely edited at the same time. Furthermore, the system includes fluorescent markers that enable successfully edited cells to be identified and tracked. In the future, this technique could be used to study how genes work together to control various characteristics, and how cancer and other diseases develop.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CRISPR/Cas9</kwd><kwd>gene editing</kwd><kwd>hematopoietic stem cells</kwd><kwd>multiplex</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Danish Council for Independent Research</institution></institution-wrap></funding-source><award-id>DFF-1333-00106B</award-id><principal-award-recipient><name><surname>Bak</surname><given-names>Rasmus O</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Stanford Child Health Research Institute</institution></institution-wrap></funding-source><award-id>Postdoctoral Award</award-id><principal-award-recipient><name><surname>Dever</surname><given-names>Daniel P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Austrian Research Council</institution></institution-wrap></funding-source><award-id>Erwin Schroedinger Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Reinisch</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001023</institution-id><institution>Amon G. Carter Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Porteus</surname><given-names>Matthew H</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research</institution></institution-wrap></funding-source><award-id>Scholar Award</award-id><principal-award-recipient><name><surname>Porteus</surname><given-names>Matthew H</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>PN2EY018244</award-id><principal-award-recipient><name><surname>Porteus</surname><given-names>Matthew H</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Stanford Ludwig Center for Cancer Stem Cell Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Majeti</surname><given-names>Ravindra</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-CA188055</award-id><principal-award-recipient><name><surname>Majeti</surname><given-names>Ravindra</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100003194</institution-id><institution>New York Stem Cell Foundation</institution></institution-wrap></funding-source><award-id>Robertson Investigator</award-id><principal-award-recipient><name><surname>Majeti</surname><given-names>Ravindra</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>Danish Council for Independent Research</institution></institution-wrap></funding-source><award-id>DFF-1331-00735B</award-id><principal-award-recipient><name><surname>Bak</surname><given-names>Rasmus O</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01- AI097320</award-id><principal-award-recipient><name><surname>Porteus</surname><given-names>Matthew H</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-AI120766</award-id><principal-award-recipient><name><surname>Porteus</surname><given-names>Matthew H</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The CRISPR/Cas9 system can be used with recombinant AAV6 donor delivery to facilitate simultaneous, targeted integration into multiple genetic loci in hematopoietic stem and progrenitor cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The current gold standard method for studying human hematopoietic stem and progenitor cell (HSPC) gene function has been either overexpression or RNAi-mediated knockdown of genes using lentiviral vectors (<xref ref-type="bibr" rid="bib13">Doulatov et al., 2012</xref>; <xref ref-type="bibr" rid="bib6">Chan et al., 2015</xref>). While these methods have provided great insights into HSPC biology, they come with several confounders, such as random integration of the vector into the host genome, unregulated transgene expression, and incomplete gene knockdown (<xref ref-type="bibr" rid="bib49">Woods et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Naldini, 2015</xref>). More recently, programmable nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 have been utilized to disrupt genes by the introduction of site-specific DNA double strand breaks (DSBs) that are corrected through non-homologous end-joining (NHEJ) (<xref ref-type="bibr" rid="bib18">Hendel et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Holt et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Saydaminova et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Mandal et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Schumann et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Kim et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Lin et al., 2014</xref>). This error-prone system creates a heterogeneous mixture of cells with various genotypes of SNPs and small insertions or deletions (INDELs); moreover, not all of the genetic changes from INDELs cause functional gene disruption as they may preserve the open reading frame and may not change amino acids essential for protein functions (<xref ref-type="bibr" rid="bib42">Shi et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Hultquist et al., 2016</xref>). In a prior study, defined gene deletions were created in HSPCs using a dual sgRNA approach, however, more than half of the alleles were not modified leading to residual gene expression (<xref ref-type="bibr" rid="bib29">Mandal et al., 2014</xref>). Another limitation of this prior study is that successfully modified cells were not distinguishable from unmodified wild type (WT) cells, and therefore could not be tracked or isolated as an enriched population. Although the versatility of the CRISPR/Cas9 system allows for simultaneous manipulation at multiple genetic loci in a single cell, multiplexing of NHEJ-based gene editing has mainly been performed in immortalized human cancer cell lines and mouse cells (<xref ref-type="bibr" rid="bib22">Hultquist et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Cong et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Heckl et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Platt et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Brown et al., 2016</xref>). Finally, these interesting multiplexed proof-of-concept studies, only used NHEJ-mediated editing and did not harness the power of homologous recombination (HR) to create more sophisticated alterations to the genome at multiple alleles and/or loci.</p><p>Here, we report an HR-mediated genome engineering method in human HSPCs and T cells that overcomes these limitations and enables the generation and enrichment of HSPC or T cell populations with complete gene knockout or gene replacement at multiple genetic loci. This method has the power to reveal functional gene networks during hematopoiesis and immune system disease pathogenesis and could be combined with the concepts of synthetic biology to create novel stem cell based therapeutics.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Enriching HSPCs with targeted integration</title><p>We and others have previously shown that HR in human HSPCs can be efficiently induced by site-specific nucleases in combination with homologous donor DNA delivered as single-stranded oligonucleotides (ssODNs), integration-defective lentiviral vectors (ÍDLVs), or by recombinant adeno-associated virus serotype 6 (rAAV6) vectors (<xref ref-type="bibr" rid="bib11">Dever et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">DeWitt et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">De Ravin et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Hoban et al., 2016</xref>). We previously showed targeted integration in the beta-globin gene (<italic>HBB</italic>) by combining delivery of Cas9 protein pre-complexed with chemically modified sgRNAs (RNP) and delivery of an AAV6 donor. After successful on-target integration of a reporter transgene, FACS-based sorting of transgene reporter<sup>high</sup>-expressing HSPCs was used to purify an HSPC population with &gt;90% targeted integration that displayed long-term repopulation capacity in NSG mice (<xref ref-type="bibr" rid="bib11">Dever et al., 2016</xref>). To extend this method beyond the <italic>HBB</italic> locus for therapeutic genome editing approaches of hemoglobinopathies, we tested six additional loci for their potential to be modified through HR by CRISPR/Cas9 in combination with AAV6-derived donor delivery. These genes are associated with hematopoiesis, hematopoietic malignancies, or safe harbor sites and include: interleukin-2 receptor gamma chain (<italic>IL2RG</italic>), chemokine (C-C motif) receptor 5 (<italic>CCR5</italic>), runt-related transcription factor one isoform c (<italic>RUNX1c</italic>), additional sex combs like 1 (<italic>ASXL1</italic>), stromal antigen 2 (<italic>STAG2</italic>), and adeno-associated virus integration site 1 (<italic>AAVS1</italic>) (<xref ref-type="bibr" rid="bib44">Tebas et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Genovese et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Patel et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Mazumdar et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Kotin et al., 1992</xref>). Following electroporation with Cas9 RNP, containing a chemically-modified sgRNA targeting a single site in the selected locus, and transduction with an rAAV6 donor vector carrying homology arms for the targeted site and an expression cassette encoding a fluorescent reporter gene (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>), we observed at early time points (day 4) a cell population with increased fluorescence intensity detectable by flow cytometry (reporter<sup>high</sup> cells) compared to cells receiving only the rAAV6 donor without electroporation of Cas9 RNP (reporter<sup>low</sup>) (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). For cells targeted at either <italic>CCR5</italic> or <italic>IL2RG,</italic> reporter<sup>high</sup>, reporter<sup>low</sup>, and reporter<sup>neg</sup> populations were sorted at day four post-electroporation and cultured up to 22 days. Reporter<sup>high</sup> populations remained 99.2 ± 0.7% reporter positive (<xref ref-type="fig" rid="fig1">Figure 1b</xref>) while sorted reporter<sup>low</sup> and reporter<sup>neg</sup> populations were 29.3 ± 5.4% and 0.6 ± 0.2% reporter positive, respectively. Dividing the reporter<sup>low</sup> cells into three sub fractions based on fluorescence intensity revealed that GFP intensity at day four post-electroporation positively correlated with the propensity for maintaining GFP expression at day 20 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b–c</xref>). In addition, single reporter<sup>high</sup> cells were plated in methylcellulose to assess integration events at the clonal level. Targeted HSPCs formed a mix of myeloid (CFU-M/GM) and erythroid colonies (BFU-E, CFU-E) indicating that they retained HSPC function. ‘In-Out PCR’ (one donor-specific primer and one locus-specific primer outside of the respective homology arms) on genomic DNA (gDNA) from single cell-derived methylcellulose colonies confirmed that 99%, 92%, and 100% of reporter<sup>high</sup> HSPCs targeted at <italic>CCR5</italic> (338 clones analyzed), <italic>IL2RG</italic> (117 clones analyzed), and <italic>RUNX1</italic> (36 clones analyzed), respectively, had at least a monoallelic targeted integration (<xref ref-type="fig" rid="fig1">Figure 1c</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Analyses of clones with only mono-allelic integration showed gene-specific differences in the modification of the non-integrated alleles ranging from 38% INDELs for <italic>IL2RG</italic> to 89% INDELs for <italic>CCR5%</italic> and 88% INDELs for <italic>RUNX1</italic>, among which the majority was gene-disrupting (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). Collectively, these data indicate that the observed log-fold transgene expression shift following rAAV6 and RNP delivery is due to HR at the intended locus and that reporter expression can be used to enrich gene-targeted HSPCs.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.27873.003</object-id><label>Figure 1.</label><caption><title>FACS-based identification and enrichment of monogenic genome-edited CD34<sup>+</sup> human hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>a</bold>) HSPCs were electroporated with <italic>CCR5</italic>-RNP and transduced with <italic>CCR5</italic>-tNGFR rAAV6 HR donor. Representative FACS plots from day four post-electroporation highlight the <italic>CCR5</italic> tNGFR<sup>high</sup> population (red gate) generated by the addition of Cas9 RNP compared to cells with low reporter expression (green gate) and reporter<sup>negative</sup> cells (black gate). Numbers reflect percentage of cells within gates. (<bold>b</bold>) Day four post-electroporation, <italic>CCR5</italic> (tNGFR or GFP) and <italic>IL2RG</italic> (GFP)-targeted HSPCs from reporter<sup>high</sup> (red), reporter<sup>low</sup> (green), and reporter<sup>neg</sup> (blue) fractions were sorted and cultured for 20-22 days while monitoring the percentage of cells that remained GFP<sup>+</sup>. Error bars represent S.E.M. <italic>N</italic> = 6 for <italic>CCR5</italic>, <italic>N</italic> = 3 for <italic>IL2RG</italic>, all from different CD34<sup>+</sup> donors. (<bold>c</bold>) HSPCs were targeted at <italic>CCR5</italic> (with GFP or tNGFR donor) or at <italic>IL2RG</italic> (GFP donor; only female cells for <italic>IL2RG</italic>). At day four post-electroporation, reporter<sup>high</sup> cells were single-cell sorted into methylcellulose for colony formation. PCR was performed on colony-derived gDNA to detect targeted integrations. 338 <italic>CCR5</italic> and 177 <italic>IL2RG</italic> myeloid and erythroid methylcellulose colonies were screened from at least two different CD34<sup>+</sup> HSPC donors. (<bold>d</bold>) HSPCs were targeted at the <italic>STAG2</italic> gene or the <italic>AAVS1</italic> locus with a GFP reporter cassette. Cells that only received the <italic>STAG</italic>2-GFP AAV6 donor and not Cas9 RNP were included as an additional control. At day four post-electroporation and transduction, reporter<sup>high</sup> cells from the <italic>STAG2</italic> and <italic>AAVS1</italic> targeting experiments and bulk cells from the <italic>STAG2</italic> AAV6 only population were plated in methylcellulose for colony formation. After 14 days, colonies were scored as either erythroid or myeloid based on morphology. Error bars represent S.E.M, N = 3, ***p&lt;0.001, n.s. = p≥0.05, unpaired t-test.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Analysis of cell fractions with different fluorescence intensity.</title><p>(<bold>a</bold>) Schematic showing the general layout of the AAV6 donors employed. ITR: inverted terminal repeat; SFFV promoter: spleen focus forming virus promoter; GFP: green fluorescent protein; polyA: bovine growth hormone polyadenylation signal; RHA: right homology arm. Approximate sizes are shown below each component. (<bold>b</bold>) Cells were targeted at the HBB locus by electroporation of Cas9 RNP followed by transduction of a homologous rAAV6 donor carrying a GFP expression cassette. At 4 days post electroporation and transduction, cells with different GFP intensities (GFP<sup>high</sup>, GFPLow<sup>High</sup>, GFPLow<sup>Med</sup>, GFPLow<sup>Low</sup>) were FACS-sorted and cultured for an additional 16 days. At day 20 post targeting, cells were analyzed for GFP expression by flow cytometry and the red gates show the GFP<sup>high</sup> population at this time point. (<bold>c</bold>) The cells from b) were analyzed at different time points after sorting, and data points show the percentage of cells within the GFP<sup>high</sup> gate for the different populations as well as a population receiving only the rAAV6 donor and not Cas9 RNP.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Genotypes of clones with mono-genic targeting.</title><p>(<bold>a</bold>) <italic>Left</italic>, schematic representation of the three-primer PCR used to genotype <italic>CCR5</italic> alleles for integrated (green PCR product) and non-integrated (red PCR product) alleles. One forward primer is located in the left homology arm (LHA), one forward primer is located in the poly A, and a common reverse primer is located outside the region of the right homology arm (RHA). <italic>Right</italic>, gel image of representative genotyped clones from <xref ref-type="fig" rid="fig1">Figure 1c</xref> (<italic>CCR5</italic>) showing colonies with biallelic and monoallelic integrations. (<bold>b</bold>) A subset of the <italic>CCR5</italic> and <italic>IL2RG</italic> clones (only female cells for <italic>IL2RG</italic>) from <xref ref-type="fig" rid="fig1">Figure 1c</xref> with monoallelic integration had the genotype on the non-integrated allele analyzed by Sanger sequencing of purified PCR products. Note that in-frame INDELs can be gene-disrupting depending on the location and size of the INDEL. (<bold>c</bold>) As in <xref ref-type="fig" rid="fig1">Figure 1c</xref>, HSPCs were targeted at <italic>RUNX1</italic> and at day four post-electroporation, reporter<sup>high</sup> cells were single cell-sorted into methylcellulose-containing 96-well plates to establish colonies. After 14 days, PCR was performed on colony-derived gDNA to detect targeted integrations. A total of 36 myeloid and erythroid methylcellulose colonies were screened. (<bold>d</bold>) The monoallelically targeted clones from c) had the genotype assessed on the non-integrated allele by Sanger sequencing of purified PCR products. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref> for complete list of genotypes.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig1-figsupp2-v2"/></fig></fig-group><p>To evaluate the applicability of this technology in a biologically relevant setting we decided to modify the cohesin complex member, <italic>STAG2,</italic> in primary CD34<sup>+</sup> HSPCs. The cohesin complex has previously been shown to play an essential part in maintaining normal erythroid differentiation potential of hematopoietic stem and progenitor cells (<xref ref-type="bibr" rid="bib30">Mazumdar et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Viny et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Mullenders et al., 2015</xref>). Since the <italic>STAG2</italic> gene is located on the human X chromosome, single-allele integration of a fluorescent reporter in male cells would be sufficient to fully knock out the gene. As expected, Cas9 RNP combined with rAAV6 donor transduction resulted in the generation of a reporter<sup>high</sup> population that could be sorted for subsequent differentiation experiments. Single cell methylcellulose assays of reporter<sup>high</sup> cells revealed an almost complete loss in the capacity to form erythroid colonies compared to cells that had only been exposed to rAAV6 and not Cas9 RNP, and also compared to cells with targeted integration at the <italic>AAVS1</italic> locus (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). These proof-of-concept studies provide evidence that gene-specific enrichment of reporter<sup>high</sup> cells can be used to study HSPC gene function.</p></sec><sec id="s2-2"><title>Biallelic targeted integration in HSPCs</title><p>To determine if this method could be used to enrich HSPCs with biallelic gene disruption, necessary for complete functional gene knockout, we targeted the <italic>ASXL1</italic> gene and simultaneously provided GFP and BFP-encoding rAAV6 donors. Four days after electroporation and transduction, 10.4% of cells were double positive for GFP<sup>high</sup> and BFP<sup>high</sup> compared to 0.2% for the AAV only sample (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Similarly, double-positive populations were apparent when targeting three other genes (<italic>RUNX1</italic>, <italic>HBB</italic>, and <italic>CCR5)</italic> with two rAAV6 donors with various color combinations (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). Double-positive cells sorted at day four after electroporation remained 94% double-positive for more than two weeks in culture (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). ‘In-out PCR’ on gDNA from single cell-derived methylcellulose clones confirmed on-target integration of one transgene into one allele and the other transgene into the second allele (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). We next tested if the biallelic targeting approach could be extended to another blood cell type and therefore targeted primary human T cells for biallelic HR at <italic>CCR5.</italic> After electroporation with <italic>CCR5</italic>-targeting Cas9 RNP followed by transduction with GFP and mCherry <italic>CCR5</italic> rAAV6 donors, a GFP<sup>high</sup>/mCherry<sup>high</sup> double-positive population was observed, indicative of biallelic integration at the <italic>CCR5</italic> gene (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). No significant toxicity was associated with biallelic targeting in T cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Overall, these results demonstrate the utility of using rAAV6, Cas9 RNP, and FACS to enrich for primary human HSPCs and T cells that have undergone biallelic homologous recombination, which may have applications for studying hematological and immunological diseases or generating HSPC or T cell therapeutics that require gene modifications or gene knockout at both alleles.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.27873.006</object-id><label>Figure 2.</label><caption><title>Identification and enrichment of biallelic genome-edited CD34<sup>+</sup> human hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>a</bold>) <italic>Left,</italic> Schematic showing biallelic targeting strategy for <italic>ASXL1</italic> using GFP and BFP-encoding rAAV6 donors for integration into each allele of <italic>ASXL1</italic>. The SFFV promoter drives reporter expression. <italic>Middle, FACS plot from an</italic> ‘AAV only’ sample day four post electroporation, showing low episomal reporter expression (BFP and GFP) in cells without the CRISPR system. <italic>Right</italic>, FACS plot of CD34<sup>+</sup> HSPCs treated with both Cas9 RNP and the two rAAV6 donors highlighting the generation of BFP<sup>high</sup>/GFP<sup>high</sup> double positive cells that have undergone <italic>ASXL1</italic> dual-allelic targeting. (<bold>b</bold>) HSPCs were targeted at both alleles of <italic>HBB</italic> (Cas9 RNP with GFP and tdTomato rAAV6 donors) and at day four post electroporation, dual positive cells were sorted and cultured for 16 days while analyzing reporter expression. Error bars representing S.E.M. are present, but too small to be visible (<italic>N</italic> = 3 different HSPC donors). (<bold>c</bold>) Gel images showing PCR genotyping of six methylcellulose-derived clones from (<bold>e</bold>) confirming integration into each of the <italic>HBB</italic> alleles. (<bold>d</bold>) Human primary T cells were CD3/CD28 stimulated for three days and then electroporated with <italic>CCR5</italic>-targeting Cas9 RNP and transduced with two <italic>CCR5</italic>-specific rAAV6 donors encoding GFP and mCherry, respectively. FACS plots show GFP<sup>high</sup>/mCherry<sup>high</sup> biallelic targeting frequencies at day four post-electroporation.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Cas9 and rAAV6-mediated biallelic homologous recombination (HR) in human CD34<sup>+</sup>HSPCs.</title><p><italic>Top</italic>, Representative FACS plots from HSPCs transduced with two rAAV6 (two fluorescent reporters for each gene), that have homology for the genes listed on the bottom panel, show low episomal expression and very few dual reporter<sup>high</sup>-expressing HSPCs. <italic>Bottom</italic>, HSPCs were electroporated with gene-specific Cas9 RNPs and then transduced with rAAV6 targeting each allele of a gene with two different indicated fluorescent reporters. FACS plots at Day 4-post electroporation highlight the dual reporter<sup>high</sup> cells that have undergone HR at both alleles of the intended gene.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Toxicity assessment of biallelic integration at the <italic>CCR5</italic> locus in primary human T cells.</title><p>Human primary T cells were isolated from buffy coats and stimulated for three days using anti-CD3 and anti-CD28 antibodies. Cells were then electroporated with <italic>CCR5</italic>-targeting Cas9 RNP and transduced with two <italic>CCR5</italic>-specific rAAV6 donors encoding GFP and mCherry, respectively, either alone or in combination. Cell viabilities were measured at Day two post-electroporation by Trypan Blue exclusion assay (<italic>N</italic> = 2 different buffy coat-derived T cells).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig2-figsupp2-v2"/></fig></fig-group></sec><sec id="s2-3"><title>Simultaneous HR-mediated targeting of two genes (Di-Genic) in HSPCs</title><p>The vast majority of hematopoietic functions and immune diseases are governed by complex, polygenic networks (<xref ref-type="bibr" rid="bib41">Seita and Weissman, 2010</xref>). To potentially study gene-gene interactions and/or generate cell therapeutics with HR modifications at two separate genes, we tested whether our methodology could facilitate simultaneous di-genic (two different genes) HR in HSPCs. We therefore co-delivered <italic>HBB</italic>-tdTomato and <italic>IL2RG</italic>-GFP rAAV6 donors with Cas9 RNP targeting both genes. This strategy produced 10.2% double positive GFP<sup>high</sup>/tdTomato<sup>high</sup> HSPCs compared to 0.1% for the AAV only control sample (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). We also generated double reporter<sup>high</sup> positive populations when testing other combinations of di-genic HR (<italic>IL2RG</italic>/<italic>CCR5, RUNX1</italic>/<italic>ASXL1</italic>, and <italic>HBB</italic>/<italic>CCR5</italic>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). Again, double reporter<sup>high</sup> positive cells sorted at day four post-electroporation remained 94% double positive for 15 days in culture (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). ‘In-Out PCR’ on double positive methylcellulose myeloid and erythroid clones showed on-target integration at both loci in 88% of clones (57 clones analyzed) (<xref ref-type="fig" rid="fig3">Figure 3c and d</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.27873.009</object-id><label>Figure 3.</label><caption><title>Identification, enrichment, and long-term engraftment in NSG mice of di-genic genome-edited CD34<sup>+</sup> human hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>a</bold>) <italic>Left,</italic> Schematic depicting <italic>HBB</italic> and <italic>IL2RG</italic> di-genic targeting. <italic>Middle,</italic> FACS plot of an ‘AAV only’ sample at day four post electroporation, showing low episomal reporter expression (<italic>HBB</italic>-tdTomato and <italic>IL2RG</italic>-GFP) in cells without the CRISPR system. <italic>Right</italic>, FACS plot at day four post-electroporation of HSPCs electroporated with Cas9 RNP targeting both <italic>HBB</italic> and <italic>IL2RG</italic> followed by transduction with <italic>HBB</italic>-tdTomato and <italic>IL2RG</italic>-GFP rAAV6 donors showing the generation of tdTomato<sup>high</sup>/GFP<sup>high</sup> cells with di-genic targeting at <italic>HBB</italic> and <italic>IL2RG</italic>. (<bold>b</bold>) Double-positive HSPCs targeted at <italic>HBB</italic> (GFP) and <italic>CCR5</italic> (mCherry) were sorted at day four post-electroporation and cultured for 15 days while analyzing reporter expression. Error bars represent S.E.M. (<italic>N</italic> = 3 different HSPC donors). (<bold>c</bold>) Representative gel images showing PCR genotyping of six (out of 57 total) <italic>HBB</italic>-GFP<sup>high</sup> (gene reporter 1)/<italic>CCR5</italic>-mCherry<sup>high</sup> (gene reporter 2) methylcellulose-derived clones confirming integration at each locus (<bold>d</bold>) Representative fluorescence microscopy images of methylcellulose-derived clones with di-genic targeting at <italic>HBB</italic> and <italic>CCR5</italic> show myeloid and erythroid progenitors with both GFP and mCherry expression. (<bold>e</bold>) HSPCs were targeted at the <italic>HBB</italic> and <italic>AAVS1</italic> loci with a GFP and BFP expression cassette, respectively. Representative FACS plot (left panel) shows analysis seven days after targeting. All four gated populations were sorted and genomic DNA was subject to TIDE analysis for determining INDEL frequencies at the two loci (middle panel), and subject to ddPCR quantification of one of the two possible monocentric translocations between <italic>HBB</italic> and <italic>AAVS1</italic> (right panel) (see also <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). (<bold>f</bold>) Representative FACS plots from cells targeted at the <italic>HBB</italic> and <italic>AAVS1</italic> loci with a GFP and BFP expression cassette, respectively. Representative FACS plot shows analysis four days after targeting at which point the four populations were sorted and transplanted intrafemorally into NSG mice that were irradiated 24 hr before transplantation. (<bold>g</bold>) Bone marrow from the injected femurs from the mice transplanted as described in (<bold>f</bold>) was analyzed 12 weeks after transplantation. Representative FACS plots are from a mouse from each of the four groups depicted in (<bold>f</bold>) as well as a mouse transplanted with mock-electroporated cells. The middle row depicts human engraftment gated as positive for the human leukocyte antigen complex (HLA-ABC). The upper and lower rows depict FACS plots gated from the human populations and show myeloid (CD33<sup>+</sup>) and lymphoid (CD19<sup>+</sup>) engraftment (upper row) as well as reporter gene expression (lower row) (see also <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref> for all transplantation data).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Cas9 and rAAV6-mediated di-genic homologous recombination (HR) in human CD34<sup>+ </sup>HSPCs.</title><p><italic>Top</italic>, Representative FACS plots of HSPCs transduced with two rAAV6 donors targeting two genes with two distinct fluorescent reporters (listed in FACS plots in lower panel) show low episomal expression and few dual reporter<sup>high</sup>-expressing HSPCs. <italic>Bottom</italic>, HSPCs were electroporated with two different gene-specific Cas9 RNPs and then transduced with homologous rAAV6 donors (each gene targeted with a different fluorescent reporter). Representative FACS plots from Day 4 post electroporation show the generation of dual reporter<sup>high</sup> positive HSPCs targeted at both genes.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig3-figsupp1-v2"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.011</object-id><label>Figure 3—figure supplement 2.</label><caption><title>Measuring translocations after <italic>HBB</italic> and <italic>AAVS1</italic> di-genic targeting.</title><p>(<bold>a</bold>) Schematic showing the <italic>HBB</italic> gene on chromosome 11 and the <italic>AAVS1</italic> locus on chromosome 19. The Cas9 cut sites are shown in red. One of the two possible monocentric translocations is shown. (<bold>b</bold>) The reference sequence of the <italic>HBB-AAVS1</italic> translocation is shown in the top. Below are representative translocation sequences from GFP<sup>-</sup>BFP<sup>-</sup> HSPCs sorted seven days after targeting (see <xref ref-type="fig" rid="fig3">Figure 3e</xref>, left panel). (<bold>c</bold>) Representative ddPCR analyses quantifying translocations in NTC (non-template control), mock-electroporated, and GFP<sup>-</sup>BFP<sup>-</sup> cells (see <xref ref-type="fig" rid="fig3">Figure 3e</xref>, right panel). The reference assay quantifies TERT gene copies used to normalize for DNA input. The translocation assay probe binds 50 bp away from the junction and none of the identified translocations would therefore exclude probe binding.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig3-figsupp2-v2"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.012</object-id><label>Figure 3—figure supplement 3.</label><caption><title>Analysis of mice transplanted with different sorted populations of cells targeted at the <italic>HBB</italic> and <italic>AAVS1</italic> locus.</title><p>The table shows an overview of the 11 NSG mice that were transplanted intrafemorally with either mock-electroporated cells or sorted cells from the four populations displayed in <xref ref-type="fig" rid="fig3">Figure 3f</xref>. 12 weeks after transplant, the transplanted femurs were flushed and the cells analyzed for human engraftment based on HLA-ABC expression, B cell or myeloid phenotype (CD19 and CD33, respectively), and expression of the two reporter genes.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig3-figsupp3-v2"/></fig></fig-group><p>Since the combination of two sgRNAs has previously been used to create and study oncogenic translocations (<xref ref-type="bibr" rid="bib27">Maddalo et al., 2014</xref>), and multiplexed TALEN-mediated gene editing in primary human T cells led to translocation frequencies between the two targeted genes of 0.01–1% with monocentric translocations occurring most frequently (<xref ref-type="bibr" rid="bib36">Poirot et al., 2015</xref>), we assessed if our di-genic targeting scheme would enrich for translocations after purification of dual-reporter positive cells. Therefore, we analyzed one of the monocentric translocations between <italic>HBB</italic> and <italic>AAVS1</italic> (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>). We targeted <italic>HBB</italic> and <italic>AAVS1</italic> with a GFP and BFP reporter, respectively, and sorted the four different populations (double negative, single positives (each gene), and double positive) seven days after targeting (<xref ref-type="fig" rid="fig3">Figure 3e</xref>, left panel). INDEL rates at <italic>HBB</italic> and <italic>AAVS1</italic> were comparable among all four sorted populations, with a small enrichment of INDELs in the three populations positive for the reporter (<xref ref-type="fig" rid="fig3">Figure 3e</xref>, middle panel). Droplet digital PCR (ddPCR) quantification of the translocation showed frequencies ranging from 0.14–0.28%, and importantly, no evidence of enrichment of the translocation was observed in the population sorted for di-genic targeting (<xref ref-type="fig" rid="fig3">Figure 3e</xref>, right panel and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c</xref>). Cloning and sequencing of PCR products spanning the translocation showed a wide variety of translocation junctions derived from different DNA end-processing products (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>).</p><p>To confirm that HSPCs with long-term and multi-lineage engraftment potential were targeted, we again targeted <italic>HBB</italic> and <italic>AAVS1</italic> with a GFP and BFP reporter, respectively, and transplanted the four different sorted populations into immune-compromised NSG mice (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). 12 weeks after transplantation, human multi-lineage engraftment was evident in the bone marrow of the transplanted mice of all four groups (<xref ref-type="fig" rid="fig3">Figure 3g</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>).</p><p>Collectively, these data show that human HSPCs that have undergone di-genic HR are not enriched for translocations, and maintain their multi-lineage colony forming capacity and long-term engraftment potential.</p></sec><sec id="s2-4"><title>Multiplexed homologous recombination in HSPCs</title><p>We next tested if we could combine the di-genic and biallelic targeting approach to simultaneously target both alleles of <italic>ASXL1</italic> (GFP and mCherry) as well as both alleles of <italic>RUNX1c</italic> (BFP and E2-Crimson) (tetra-allelic) (for schematic see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>). Delivery of Cas9 RNPs targeting both genes followed by transduction of four rAAV6 donors gave rise to 1.1% GFP<sup>high</sup>/mCherry<sup>high</sup>/BFP<sup>high</sup>/E2Crimson<sup>high</sup> quadruple-positive cells (<xref ref-type="fig" rid="fig4">Figure 4a</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b–c</xref>). A similar quadruple-positive population was evident when targeting all four combined alleles of <italic>HBB</italic> and <italic>RUNX1c</italic> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1e–h</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). Mixed, myeloid, and erythroid colonies were formed at frequency and ratio comparable to AAV only controls (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Genotyping of colonies revealed on-target integration at both alleles at both loci in 78% of clones (73 clones analyzed) (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). Flow-cytometric analysis of individual colonies confirmed expression of all four reporters (BFP/GFP/mCherry/E2Crimson) at high levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1d</xref>). The total number of genetic changes in this enriched population, which could be used for synthetic biology purposes is six: two endogenous genes inactivated (both alleles of each gene) plus the addition of four different transgenes (represented in our experiment by four genes encoding different fluorescent proteins). Thus, this methodology could be used for studying interaction of genes that need both copies disrupted to lose function, such as tumor suppressor genes.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.27873.013</object-id><label>Figure 4.</label><caption><title>Multiplexing homologous recombination in CD34<sup>+</sup> human hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>a</bold>) HSPCs were electroporated with Cas9 RNP targeting <italic>ASXL1</italic> and <italic>RUNX1</italic> followed by rAAV6 transduction with two donors for <italic>ASXL1</italic> (mCherry and GFP) and two donors for <italic>RUNX1</italic> (E2Crimson and BFP). Tetra-allelically targeted HSPCs were identified as mCherry<sup>high</sup>/GFP<sup>high</sup>/BFP<sup>high</sup>/E2Crimson<sup>high</sup> (<italic>N</italic> = 3 see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>) (<bold>b</bold>) Cells modified at both alleles for <italic>RUNX1</italic> and <italic>ASXL1</italic> (as in (<bold>a</bold>)) were subjected to a methylcellulose assay (triplicates) and scored as BFU-E, CFU-M, CFU-GM or CFU-GEMM based on morphology 14 days after sorting. (<bold>c</bold>) PCR was performed on colony-derived gDNA to detect targeted integrations at both genes. 73 individual colonies were analyzed. Color coding for colonies with triple-allelic integration are as follows: grey: <italic>RUNX1</italic> biallelic/<italic>ASXL</italic> monoallelic; white: <italic>RUNX1</italic> monoallelic/<italic>ASXL1</italic> biallelic. (<bold>d</bold>) For tri-genic targeting of HSPCs, cells were electroporated with Cas9 RNP targeting <italic>IL2RG</italic>, <italic>HBB</italic>, and <italic>CCR5</italic> followed by transduction of three rAAV6 donors homologous to each of the three genes (<italic>IL2RG</italic>-GFP, <italic>HBB</italic>-tdTomato, and <italic>CCR5</italic>-tNGFR). Tri-genic-targeted cells were identified as reporter<sup>high</sup> for all three reporters (<italic>N</italic> = 5 see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). (<bold>e</bold>) Methylcellulose clones from the triple-positive cells in (<bold>d</bold>) were subjected to genotyping PCR and gel images show colonies with targeted integration at all three genes in 9/11 colonies (note that GFP shows a faint band in colony 6). (<bold>f</bold>) <italic>Left</italic>, Schematic showing strategy for targeting four different genes (<italic>HBB</italic>, <italic>RUNX1</italic>, <italic>ASXL1</italic>, and <italic>CCR5</italic>) simultaneously (tetra-genic). Four different genes are targeted by electroporation of four different Cas9 RNPs followed by transduction with four different rAAV6 donors that each targets a gene with a different reporter. <italic>Right</italic>, Tetra-genic targeting at the above-mentioned four genes was identified as reporter<sup>high</sup> for all four reporters (<italic>N</italic> = 3 see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.014</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Targeting two genes for biallelic homologous recombination (HR) in primary CD34<sup>+</sup> HSPCs.</title><p>(<bold>a</bold>) Schematic showing experimental strategy for <xref ref-type="fig" rid="fig4">Figure 4a</xref> for targeting both alleles of <italic>RUNX1</italic> and <italic>ASXL1</italic>. (<bold>b</bold>) FACS plots, gating scheme, and frequencies of HR at each allele for the experiment shown in <xref ref-type="fig" rid="fig4">Figure 4a</xref>. (<bold>c</bold>) FACS plot showing very low frequency of tetra-reporter<sup>high</sup> cells without Cas9. (<bold>d</bold>) FACS plots of cells from single methylcellulose colonies derived from tetra-reporter<sup>high</sup> cells from <xref ref-type="fig" rid="fig4">Figure 4a</xref>. (<bold>e</bold>) Schematic showing targeting both alleles of <italic>RUNX1</italic> and <italic>HBB</italic> for HR with four distinct reporters. (<bold>f</bold>) <italic>Top</italic>, FACS plots of HSPCs transduced with four rAAV6s (no Cas9 RNPs) showing the gating scheme and low episomal reporter expression without a nuclease. <italic>Bottom</italic>, HSPCs were electroporated with RNPs targeting <italic>HBB</italic> and <italic>RUNX1</italic> and then transduced with four rAAV6s. FACS plots from day four post electroporation show MFI shift for each reporter alone. <italic>HBB</italic>-tNGFR rAAV6 has reproducibly shown lower episomal expression than all other rAAV6 we have used. (<bold>g</bold>) Images from fluorescence microscopy showing an mCherry/BFP/GFP positive CFU-GM clone that has undergone tetra-allelic HR. The colony was not stained for <italic>HBB</italic>-tNGFR. (<bold>h</bold>) <italic>Left</italic>, FACS plots show very low frequency of tetra-reporter<sup>high</sup> cells without Cas9. <italic>Right</italic>, Nuclease addition increases the frequency of bi and tetra-reporter<sup>high</sup> HSPCs.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-figsupp1-v2"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.015</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Multiplexing homologous recombination at three genes simultaneously in HSPCs.</title><p>(<bold>a</bold>) Schematic showing experimental strategy for <xref ref-type="fig" rid="fig4">Figure 4d</xref> targeting three genes, <italic>IL2RG</italic>, <italic>CCR5</italic>, and <italic>HBB</italic>. (<bold>b</bold>) FACS plots show gating scheme and HR frequencies at each locus for the experiment shown in <xref ref-type="fig" rid="fig4">Figure 4d</xref>. (<bold>c</bold>) Schematic outlining another tri-genic targeting experiment for <italic>RUNX1</italic>, <italic>ASXL1,</italic> and <italic>HBB</italic>. (<bold>d</bold>) <italic>Top</italic>, FACS plots of HSPCs transduced with three rAAV6 donors (no RNPs). <italic>Bottom</italic>, HSPCs were electroporated with gene-specific RNPs and then transduced with three rAAV6 donors. FACS plots at Day 4-post electroporation show MFI shift for each reporter alone. (<bold>e</bold>) FACS plots from same sample as in (<bold>d</bold>), but showing different combinations of di-genic reporter<sup>high</sup> populations that contain the same frequency of tri-genic reporter<sup>high</sup> cells.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-figsupp2-v2"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.016</object-id><label>Figure 4—figure supplement 3.</label><caption><title>Toxicity assessment of multiplexed HR.</title><p>CD34<sup>+</sup> cells from mobilized peripheral blood were targeted at one, two, or three genes with Cas9 RNP and rAAV6 donors. Viabilities were measured by flow cytometry 72 hr post-electroporation using Live/Dead and Annexin V stains. Viable cells are defined as live, non-apoptotic (Annexin V<sup>−</sup>) and plotted as percentage of a single AAV6 donor alone. Error bars represent SD, ns = not statistically significant, Mann-Whitney test, <italic>N</italic> = 2 different HSPC donors.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-figsupp3-v2"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.017</object-id><label>Figure 4—figure supplement 4.</label><caption><title>Assessment of false-positive frequencies of FACS-based identification of multiplexed HR in HSPCs.</title><p>Since capture of rAAV6 donors at the site of a DSB via NHEJ has been reported, we measured the false-positive rate of multiplexing HR via flow cytometry. (<bold>a</bold>) False-positive frequencies of di-genic targeting in HSPCs was determined by electroporating cells with an <italic>HBB</italic>-targeting Cas9 RNP followed by transduction with <italic>HBB</italic>-GFP (homologous) and <italic>CCR5</italic>-mCherry (non-homologous) rAAV6 donors. FACS plots show a false-positive rate of 0.24% dual reporter<sup>high</sup> cells. Note that 4% dual reporter<sup>high</sup> cells was reported in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> when performing di-genic targeting at <italic>CCR5</italic> and <italic>HBB</italic>, giving a false positive rate of 6% of targeting. (<bold>b</bold>) <italic>Left</italic>, To determine false-positive frequencies of tri-genic targeting in HSPCs, we electroporated <italic>IL2RG</italic>-RNP and <italic>HBB</italic>-RNP into HSPCs followed by transduction with the rAAV6 donors <italic>IL2RG</italic>-GFP (homologous), <italic>HBB</italic>-tdTomato (homologous), and <italic>CCR5</italic>-tNGFR (non-homologous). FACS plots show a false-positive frequency of 0.47%. Note that <xref ref-type="fig" rid="fig4">Figure 4d</xref> shows a tri-genic targeting frequency of 4.1% (a false-positive rate of 11% of targeting). <italic>Right</italic>, We employed a similar strategy to determine false-positive frequencies of tri-genic targeting, but this time used different combinations of on-target nucleases. The false-positive rate detected here was 0.1% (2.4% of targeting). (<bold>c</bold>) To determine tetra-genic false-positive frequencies, we electroporated HSPCs with three on-target nucleases (<italic>IL2RG</italic>, <italic>HBB</italic>, and <italic>CCR5</italic>) and then transduced with three homologous rAAV6 donors (<italic>IL2RG</italic>, <italic>HBB</italic>, and <italic>CCR5</italic>) and one non-homologous donor (<italic>CXCL12</italic>). FACS plots show a frequency of 0.09% that are reporter<sup>high</sup> for all four reporters with <xref ref-type="fig" rid="fig4">Figure 4f</xref> showing a tetra-genic targeting frequency of 1.0% (a false-positive rate of 9% of targeting).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-figsupp4-v2"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.27873.018</object-id><label>Figure 4—figure supplement 5.</label><caption><title>Controlling genotype with cDNA knock-in.</title><p>(<bold>a</bold>) A heterozygous knockout population can be generated with two HR donors. The first donor is designed to knock-in a wild-type (WT) cDNA cassette into the start codon (ATG) of the gene of interest followed by a cassette encoding a reporter gene (here GFP). WT cDNA is expressed from the endogenous promoter as reported by <xref ref-type="bibr" rid="bib46">Voit et al. (2014)</xref>, <xref ref-type="bibr" rid="bib21">Hubbard et al. (2016)</xref>, and <xref ref-type="bibr" rid="bib11">Dever et al. (2016)</xref>, which maintains endogenous regulatory control over gene expression. The other donor encodes another reporter (here BFP), which disrupts the targeted gene. Double positive cells (GFP<sup>+</sup>/BFP<sup>+</sup>) are heterozygous for the knockout allele. (<bold>b</bold>) A population heterozygous for a particular SNP can be generated using two donors that knock in cDNA expression cassettes followed by different reporter genes. One cDNA is WT while the other carries the SNP of interest. Double positive cells (GFP<sup>+</sup>/BFP<sup>+</sup>) are heterozygous for the SNP allele. Endogenous 3’ UTRs may be incorporated to preserve posttranscriptional regulation. Heterozygous SNP cDNA knock-in may be expanded to two or more genes, which may be of particular interest in studies of leukemia-mutated genes such as <italic>DNMT3A</italic>, <italic>IDH1/2</italic>, <italic>JAK2</italic>, and <italic>KRAS</italic>, which often occur in various combinations as heterozygous gain-of-function or dominant negative mutations. In addition, reporter knock-in combined with WT cDNA knock-in (as depicted in a) as well as SNP cDNA knock-in (SNP that disrupts gene or gene function) combined with WT cDNA knock-in (as depicted in b) could be used to study haploinsufficiencies. Though not depicted, all genes in the schematic are followed by polyadenylation signals.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-27873-fig4-figsupp5-v2"/></fig></fig-group><p>Multi-genic HR in HSPCs would allow for the characterization of functional gene networks during human hematopoiesis (<xref ref-type="bibr" rid="bib5">Bystrykh et al., 2005</xref>). To validate that our methodology could multiplex HR in HSPCs in more than two genes simultaneously, we electroporated HSPCs with RNPs targeting <italic>HBB</italic>, <italic>CCR5</italic>, and <italic>IL2RG</italic>, and then transduced them with gene-specific rAAV6 donors (<italic>HBB-</italic>tdTomato, <italic>CCR5-</italic>tNGFR, <italic>IL2RG-</italic>GFP) (for schematic see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref>). At day four post-electroporation, 4.1% of HSPCs were triple-positive (<xref ref-type="fig" rid="fig4">Figure 4d</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b</xref>). ‘In-Out PCR’ on gDNA from myeloid and erythroid colonies derived from this population showed that 78% (27 clones analyzed) had an integration event at all 3 loci, indicating at least mono-allelic integrations at each targeted locus (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). Further analyses showed that 85% of these clones with tri-genic integrations were modified on all alleles either by biallelic integration or INDELs on the non-integrated allele that were mostly disruptive (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>). These data confirm that the methodology can efficiently enrich for HSPCs with multiplexed HR. Targeting at another combination of three genes (<italic>RUNX1/HBB/ASXL1</italic>) showed 2.9% triple-positive cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c–e</xref>), and collectively, tri-genic targeting experiments yielded an average of 4.5% triple-positive cells, with the highest frequency of 14% (<italic>N</italic> = 5) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). To test if multiplexing HR caused cellular senescence or more cell death than mono or di-genic targeting in HSPCs, we evaluated cell death and apoptosis rates at day three post-targeting and proliferation for up to 10 days post-targeting (corresponding to 7 days post-sorting). We observed similar proliferation rates comparing modified and unmodified cells (data not shown) and only a minor, non-statistically significant decrease in cell viability (p=0.333) when targeting three genes compared to one (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Finally, we targeted HSPCs for tetra-genic HR (<italic>HBB</italic>, <italic>CCR5</italic>, <italic>ASXL1</italic>, <italic>RUNX1</italic>) and found after four days in culture that 1% of cells were reporter<sup>high</sup> positive for all four reporters (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). Targeting the same four genes with other combinations of reporter genes gave 0.41% and 0.78% tetra-genic targeting frequencies in the total cell population (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). Strikingly, 41–71% of HSPCs with tri-genic HR had undergone tetra-genic HR, suggesting that HR events at different genes may not be independent of each other, in contrast to recent findings for multiplexed NHEJ (<xref ref-type="bibr" rid="bib22">Hultquist et al., 2016</xref>). Because rAAV vectors can be captured at DSBs via NHEJ (<xref ref-type="bibr" rid="bib31">Miller et al., 2004</xref>), we performed experiments that aimed to detect the frequency of capture events by including a non-homologous rAAV donor in targeting experiments. We found that 89–98% of reporter<sup>high</sup> cells were derived from on-target homologous recombination, confirming a relatively low rate of AAV capture (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p><xref ref-type="table" rid="table1">Table 1</xref> summarizes the HR multiplex experiments (seven total genes targeted) and shows that by using Cas9 RNP, rAAV6, and flow cytometry-based sorting, we can reproducibly generate HSPC populations that have undergone HR events at multiple loci. For synthetic biology purposes, the tetra-genic targeting method, for example, can generate an enriched population of cells with eight genetic modifications: the knockout of at least a single allele of four different genes while introducing four different transgenes (in this proof-of-concept we used three fluorescent protein reporter genes and one biologically inert cell surface marker (tNGFR) that has been previously used in human clinical trials to track genetically modified hematopoietic stem cells over the course of decades). Our approach to studying gene function in human HSPCs has several advantages over lentiviral-based approaches because it enables: (1) multigenic targeted integration (at least four genes), (2) enrichment of highly pure edited populations, (3) the ability to trace cells with a specific genotype, (4) enrichment of a population with biallelic targeting of at least two genes, and (5) fluorescent protein-based hematopoietic cell lineage tracing. Our methodology has the potential to advance the biological understanding of gene functions in canonical HSC processes, including self-renewal, differentiation, and engraftment, all of which are critical aspects of fundamental stem cell biology and may augment the efficacy of stem cell based therapeutics.</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.27873.019</object-id><label>Table 1.</label><caption><title>Overview of targeting experiments in hematopoietic stem and progenitor cells (HSPCs).</title><p>Overview of all HSPC targeting experiments performed in this study with the number of independent experiments (N) for each experiment type, and the mean targeting efficiency (±SD). See also <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a, c, and e</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Experiment</th><th>N</th><th>% efficiency ± SD</th></tr></thead><tbody><tr><td>Monogenic</td><td>47</td><td>21.7 ± 13.4</td></tr><tr><td>Biallelic</td><td>16</td><td>5.5 ± 4.2</td></tr><tr><td>Di-genic</td><td>17</td><td>8.1 ± 8.1</td></tr><tr><td>Tetra-allelic</td><td>3</td><td>0.9 ± 0.3</td></tr><tr><td>Tri-genic</td><td>6</td><td>4.5 ± 4.8</td></tr><tr><td>Tetra-genic</td><td>3</td><td>0.7 ± 0.3</td></tr></tbody></table></table-wrap><p>By knocking in four different transgenes into four different genes, the method generates four gene disruptions and four gene additions. However, the use of multiple sgRNAs also increases the chances for off-target effects and chromosomal translocations. By looking for monocentric translocations between two genes (<italic>HBB and AAVS1</italic>), we observed low levels of translocation events similar to previously published studies (<xref ref-type="bibr" rid="bib36">Poirot et al., 2015</xref>). Such effects are likely sgRNA and target gene-specific and need to be assessed on a case-by-case basis. The observed tetra-genic targeting efficiencies at &gt;0.5% are high enough to be experimentally useful, and though some applications may be restricted by HSPC source and starting cell numbers, our targeting methodology may be combined with recent advances in HSPC expansion protocols (<xref ref-type="bibr" rid="bib15">Fares et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Cutler et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">de Lima et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Popat et al., 2015</xref>) or with transplantation into a humanized bone marrow ossicle xenotransplantation model, which supports higher engraftment levels compared to a standard NSG model (<xref ref-type="bibr" rid="bib38">Reinisch et al., 2016</xref>). By using reporters as transgenes, one can both enrich and track the modified cells, and by using a transgene cassette in which a potentially biologically active transgene is linked through a 2A peptide or IRES to a reporter gene, one can enrich and track cells that could have up to four different new potentially bioactive genes expressed. Additionally, we and others have recently demonstrated the feasibility of knocking in a cDNA immediately after the start codon of the gene, thereby maintaining endogenous regulatory control over gene expression (<xref ref-type="bibr" rid="bib11">Dever et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Hubbard et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Voit et al., 2014</xref>). This provides a genetic engineering toolbox where different types of alleles (WT, knockout, mutant cDNA forms) are fluorescently tagged and can be enriched or tracked in a population with mixed allele combinations. One potential caveat is the requirement for reporter gene expression and the fact that cells must be cultured for 2–3 days until reporter gene expression is detectable and cells can be sorted. Even though we have not detected any obvious negative impact in this or previous studies (<xref ref-type="bibr" rid="bib11">Dever et al., 2016</xref>; <xref ref-type="bibr" rid="bib2">Bak and Porteus, 2017</xref>), future studies may further investigate and optimize ex vivo culturing conditions, as well as promoter and reporter choice for minimal impact on biology and repopulation potential of edited HSPCs.</p><p>Our methodology could be used for the characterization of gene interactions during blood and immune system disease pathogenesis. For example, functional knockouts can be created at one gene (e.g. reporter knock-in into tumor suppressor gene), while introducing disease-causing polymorphisms at another gene (cDNA expression cassette knock-in into proto-oncogene) (see <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref> for schematic). For example, Zhao et al., showed that the loss of p53 cooperates with the <italic>Kras<sup>G12D</sup></italic> mutation to promote acute myeloid leukemia (AML) in mouse HSPCs using a retroviral methodology (<xref ref-type="bibr" rid="bib50">Zhao et al., 2010</xref>). Our system could be used to address whether these findings can be translated to human HSPCs by achieving site specific HR that would simultaneously knock out a tumor suppressor (e.g. <italic>TP53</italic>) and drive mutant <italic>KRAS</italic> under endogenous regulatory conditions, instead of using strong constitutive exogenous viral promoters with little control over proviral copy number and heterogeneity of transgene expression. However, in cDNA knock-in experiments, proper expression should always be validated since elements in the adjacent reporter expression cassette or the lack of UTRs and introns could influence cDNA expression (<xref ref-type="bibr" rid="bib43">Sweeney et al., 2017</xref>). We also show biallelic integration in primary human T cells at <italic>CCR5</italic>, which could be therapeutically applicable for engineering HIV-resistance, where biallelic knockout of <italic>CCR5</italic> could be combined with expression of different HIV restriction factors (<xref ref-type="bibr" rid="bib47">Voit et al., 2013</xref>). Additionally, this approach could be useful to extend recently published studies showing high potency of chimeric antigen receptors (CARs) that were site-specifically integrated into the TRAC gene using CRISPR and AAV6 in primary human T cells (<xref ref-type="bibr" rid="bib14">Eyquem et al., 2017</xref>). Multiplexed gene editing may be used to knock-in different CARs or co-stimulatory ligands into genes that are desirable to knock-out in CAR T cell therapy. We anticipate in the future that multiplexed HR mediated cell engineering will facilitate even more sophisticated uses of synthetic biology-based stem cell therapeutics than the examples we have given. Our methodology should also be widely applicable to other cell types of the hematopoietic system besides HSPCs and T cells, and even to cells of non-hematopoietic origin.</p><p>In conclusion, we anticipate that this method will be applicable to studying human hematopoiesis and immune system disease pathogenesis through multiplexed, site-specific genome engineering by HR, which has the potential to lead to new discoveries in human hematopoietic stem cell biology.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>AAV vector production</title><p>AAV vector plasmids were cloned in the pAAV-MCS plasmid (Agilent Technologies, Santa Clara, CA) containing ITRs from AAV serotype 2 (AAV2). <italic>CCR5</italic>, <italic>IL2RG</italic>, <italic>HBB</italic>, <italic>RUNX1</italic>, <italic>ASXL1</italic>, and <italic>CXCL12</italic> vectors contained an SFFV promoter, a reporter gene such as tNGFR, MaxGFP (or Citrine), BFP, mCherry, tdTomato or E2Crimson and BGH polyA. MaxGFP and Citrine are referred to as GFP throughout. For translocation and NSG transplantation experiments, a UbC promoter (approx. 1200 bp) was used in the <italic>HBB</italic> donor instead of an SFFV promoter. For the T cell experiments, donors carried an EF1α promoter (approx. 1200 bp). The homology arms for <italic>IL2RG, ASXL1,</italic> and <italic>CCR5</italic> were 800 bp, whereas left and right homology arms for <italic>HBB</italic> were 540 bp and 420 bp, respectively. The homology arms for <italic>RUNX1, STAG2,</italic> and AAVS1 were 400 bp. CCR5 donors used in T cell experiments expressed Citrine or mCherry from the PGK promoter and contained 400 bp homology arms. rAAV6 vectors were produced as described with a few modifications (<xref ref-type="bibr" rid="bib23">Khan et al., 2011</xref>). Briefly, 293FT cells (Life Technologies, Carlsbad, CA, USA) were seeded at 13 × 10<sup>6</sup> cells per dish in ten 15 cm dishes one day before transfection. Each 15 cm dish was transfected using standard PEI transfection with 6 μg ITR-containing plasmid and 22 μg pDGM6 (gift from David Russell, University of Washington, Seattle, WA, USA), which contains the AAV6 cap genes, AAV2 rep genes, and adenovirus five helper genes. Cells were incubated for 72 hr until rAAV6 was harvested from cells by three freeze-thaw cycles followed by a 45 min incubation with TurboNuclease (Abnova, Heidelberg, Germany) or Benzonase (Thermo Fisher) at 250 U/mL. AAV vectors were purified on an iodixanol density gradient by ultracentrifugation at 48,000 rpm for 2.25 hr at 18°C. AAV vectors were extracted at the 58–40% iodixanol interface and dialyzed three times in PBS with 5% sorbitol in the last dialysis using a 10K MWCO Slide-A-Lyzer G2 Dialysis Cassette (Thermo Fisher Scientific, Santa Clara, CA, USA). Vectors were added pluronic acid to a final concentration of 0.001%, aliquoted, and then stored at −80°C until further use. rAAV6 vectors were titered using quantitative PCR to measure number of vector genomes as described before (<xref ref-type="bibr" rid="bib1">Aurnhammer et al., 2012</xref>).</p></sec><sec id="s4-2"><title>CD34<sup>+</sup> hematopoietic stem and progenitor cells</title><p>Frozen CD34<sup>+</sup> HSPCs derived from mobilized peripheral blood or cord blood were purchased from AllCells (Alameda, CA, USA) and thawed according to manufacturer’s instructions. Fresh CD34<sup>+</sup> HSPCs from cord blood were acquired from donors under informed consent via the Binns Program for Cord Blood Research at Stanford University and used without freezing. Fresh CD34<sup>+</sup> HSPCs from bone marrow were obtained from Stanford BMT Cell-Therapy Facility after informed consent. CD34<sup>+</sup> cells were isolated using a human CD34 MicroBead Kit (Miltenyi Biotec, San Diego, CA, USA). Generally, CB-derived HSPCs perform better in HR experiments. CD34<sup>+</sup> HSPCs were cultured in stem cell retention media consisting of StemSpan SFEM II (Stemcell Technologies, Vancouver, Canada) supplemented with SCF (100 ng/ml), TPO (100 ng/ml), Flt3-Ligand (100 ng/ml), IL-6 (100 ng/ml), UM171 (Stemcell Technologies) (35 nM) and StemRegenin1 (0.75 mM). Mycoplasma contamination testing was not performed. Cells were cultured at 37°C, 5% CO<sub>2</sub>, and 5% O<sub>2</sub>.</p></sec><sec id="s4-3"><title>T cell isolation and culturing</title><p>Primary human CD3<sup>+</sup> T cells were isolated from buffy coats obtained from the Stanford School of Medicine Blood Center using a human T Cell Isolation Kit (Miltenyi) according to manufacturer’s instructions. Cells were cultured in X-VIVO 15 (Lonza, Walkersville, MD, USA) containing 5% human serum (Sigma-Aldrich, St. Louis, MO, USA), 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, NJ, USA) and 10 ng/ml human rIL-7 (BD Biosciences, San Jose, CA, USA). T cells were activated directly after isolation with immobilized anti-CD3 antibody (clone: OKT3, Tonbo Biosciences, San Diego, CA, USA) and soluble anti-CD28 antibody (clone: CD28.2, Tonbo Biosciences) for 72 hr. Mycoplasma contamination testing was not performed. T cells were cultured at 37°C, 5% CO<sub>2</sub>, and ambient oxygen levels.</p></sec><sec id="s4-4"><title>Electroporation and transduction of cells</title><p>All synthetic sgRNAs were purchased from TriLink BioTechnologies (San Diego, CA, USA). sgRNAs were chemically modified with three terminal nucleotides at both the 5′ and 3′ ends containing 2′ O-Methyl 3′ phosphorothioate and HPLC-purified. The genomic sgRNA target sequences with PAM in bold) were: <italic>HBB</italic>: 5’-CTTGCCCCACAGGGCAGTAA<bold>CGG</bold>-3’, <italic>CCR5</italic>: 5’-GCAGCATAGTGAGCCCAGAA<bold>GGG</bold>-3’, <italic>IL2RG</italic>: 5’-TGGTAATGATGGCTTCAACA<bold>TGG</bold>-3’, <italic>RUNX1c</italic>: 5’-TACCCACAGTGCTTCATGAG<bold>AGG</bold>-3’ <italic>ASXL1</italic>: 5’-ACAGATTCTGCAGGTCATAG<bold>AGG</bold>-3’, <italic>STAG2:</italic> 5’-AGTCCCACATGCTATCCACA<bold>AGG</bold>-3’, AAVS1: 5’-GGGGCCACTAGGGACAGGAT<bold>TGG</bold>-3’. Cas9 protein was purchased from Life Technologies and Integrated DNA Technologies. Cas9 RNP was made by incubating protein with sgRNA at a molar ratio of 1:2.5 at 25°C for 10 min immediately prior to electroporation into CD34<sup>+</sup> HSPCs or T cells. CD34<sup>+</sup> HSPCs were electroporated 1–2 days after thawing or isolation. T cells were electroporated three days following activation. Both CD34<sup>+</sup> HSPCs and T cells were electroporated using the Lonza Nucleofector 2b (program U-014) or 4D (program EO-100) (we have not detected any device-specific differences in electroporation efficiencies) and the Human T Cell Nucleofection Kit (VPA-1002, Lonza) with the following conditions: 5 × 10<sup>6</sup> cells/ml, 150–300 µg/ml Cas9 protein complexed with sgRNA at 1:2.5 molar ratio. Following electroporation, cells were incubated for 15 min at 37°C after which they were added rAAV6 donor vectors (generally at an MOI (vector genomes/cell) of 50,000–100,000 for each gene). A mock-electroporated control was included in most experiments where cells were handled the same and was electroporated in the same electroporation buffer, but without Cas9 RNP. For experiments targeting multiple loci, electroporation volume and cell numbers were kept the same as stated above, and 150–300 µg/ml Cas9 RNP and MOIs of 50,000–100,000 were used for each targeted locus, but with no more than a total of 60 ug Cas9 per electroporation and 200,000 vector genomes/cell. All AAV vectors were added simultaneously and directly to the cell culture after which the cells were transferred to the incubator without further manipulation. AAV volume was kept less than 20% of the total culturing volume and medium was either supplemented or replaced with fresh medium after overnight culture.</p></sec><sec id="s4-5"><title>Measuring multiplexed targeted integration of fluorescent and tNGFR donors</title><p>Reporter<sup>high</sup> expression was measured by flow cytometric analyses after 3–4 days post-electroporation and transduction using gates for multiplexed targeted integration set so that ‘AAV only’ samples (no nuclease) were less than 1% since previous data (not presented) have shown that after ~14 days in culture the frequency of reporter<sup>+</sup> cells (from persistent episomal expression, random integration, and/or non-nuclease mediated HR) is generally less than 1%. The truncated NGFR receptor (tNGFR) where the cytoplasmic intracellular signaling domain is removed and is signaling incompetent, solely served the purpose of a reporter for targeted CD34<sup>+</sup> HSPCs in indicated experiments (<xref ref-type="bibr" rid="bib3">Bonini et al., 2003</xref>). Targeted integration of a tNGFR expression cassette was measured by flow cytometry of cells stained with APC-conjugated anti-human CD271 (NGFR) antibody (clone: ME20.4, BioLegend, San Diego, CA). For enriching of reporter<sup>high</sup> populations, cells were sorted on a FACS Aria II SORP using DAPI, PI (both Thermo Fisher, 1 µg/ml) or LIVE/DEAD Fixable Cell Stain Kit (Life Technologies) to discriminate live and dead cells according to manufacturer's instructions.</p></sec><sec id="s4-6"><title>Scoring, FACS-analysis, and genotyping of methylcellulose colonies</title><p>Single reporter<sup>high</sup> cells were either single-cell sorted into 96-well plates (Corning) pre-filled with 100 µl of methylcellulose and water in the outer wells or plated at 500 cells per 6 cm dish with methylcellulose (Methocult, StemCell Technologies). After 14 days, colonies were counted and scored as BFU-E, CFU-M, CFU-GM and CFU-GEMM according to the manual for ‘Human Colony-forming Unit (CFU) Assays Using MethoCult’ from StemCell Technologies and prior expertise (<xref ref-type="bibr" rid="bib28">Majeti et al., 2007</xref>). For DNA extraction from 96-well plates, PBS was added to wells with colonies, and the contents were mixed and transferred to a U-bottomed 96-well plate. From 6 cm dishes, colonies were picked and transferred to PBS. Cells were pelleted by centrifugation at 300xg for 5 min followed by a wash with PBS. Finally, cells were resuspended in 25 µl QuickExtract DNA Extraction Solution (Epicentre, Madison, WI, USA) and transferred to PCR plates, which were incubated at 65°C for 10 min followed by 100°C for 2 min. For <italic>CCR5</italic>, a 3-primer PCR was set up with a forward primer binding in the left homology arm, a forward primer binding in the insert, and a reverse primer binding in CCR5 outside the right homology arm CCR5_inside_LHA: 5’-GCACAGGGTGGAACAAGATGG-3’, CCR5_insert: 5’-AAGGGGGAGGATTGGGAAGAC-3’, CCR5_outside_RHA: 5’-TCAAGAATCAGCAATTCTCTGAGGC-3’. For all other genes, gene-specific integration was detected by ‘In-Out’ PCR using a primer that binds outside the homology arm (HA) and a primer specific for the transgene cassette (insert). <italic>HBB</italic>_outside_LHA: GAAGATATGCTTAGAACCGAGG, <italic>HBB</italic>_insert: ACCGCAGATATCCTGTTTGG <italic>IL2RG</italic>_insert: 5’-GTACCAGCACGCCTTCAAGACC-3’, <italic>IL2RG</italic>_outside_RHA: 5’-CAGATATCCAGAGCCTAGCCTCATC-3’, <italic>RUNX1</italic>_outside_RHA: 5’- GAAGGGCATTGCTCAGAAAA-3’, <italic>RUNX1</italic>_insert: 5’- AAGGGGGAGGATTGGGAAGAC-3’, <italic>ASXL1</italic>_outside_RHA: 5’- AAGGGGGAGGATTGGGAAGAC-3’, <italic>ASXL1</italic>_insert: 5’- CCTCCCAAGCTGGAACTACA-3’. For detecting IL2RG non-integrated (non_int) alleles the following primers were used: IL2RG_non_int_fw: 5’-TCACACAGCACATATTTGCCACACCCTCTG-3′, IL2RG_non_int_rv: 5′-TGCCCACATGATTGTAATGGCCAGTGG-3’. For detecting dual integration of GFP and tdTomato into two <italic>HBB</italic> alleles, a primer in <italic>HBB</italic> outside the right homology arm was used together with either a GFP or tdTomato-specific primer: <italic>HBB</italic>_outside_RHA: 5’-GATCCTGAGACTTCCACACTGATGC-3’, GFP: 5’-GTACCAGCACGCCTTCAAGACC-3’, tdTomato: 5’-CGGCATGGACGAGCTGTACAAG-3’. Clones with di-genic GFP (<italic>HBB</italic>)/mCherry (<italic>CCR5</italic>) and tri-genic GFP (<italic>IL2RG</italic>)/tdTomato (<italic>HBB</italic>)/tNGFR (<italic>CCR5</italic>) integrations were screened for integrations using the same primers as above. All integrated PCR bands were subjected to Sanger sequencing to confirm perfect HR at the intended locus. For flow-cytometric analysis of colonies generated from cells with quadruple-allelic HR, individual colonies were picked and directly resuspended in FACS buffer containing LIVE/DEAD staining solution (LIVE/DEAD Fixable Near-IR Dead Cell Stain, Thermo). After 30 min incubation (4°C, dark) cells were washed in FACS buffer and subjected to analysis. Dead cells were excluded from analysis based on APC-Cy7 positivity.</p></sec><sec id="s4-7"><title>Transplantation of CD34<sup>+</sup> HSPCs into NSG mice</title><p>6 to 8 week-old NOD scid gamma (NSG) mice were used (Jackson laboratory, Bar Harbor, ME USA). The experimental protocol was approved by Stanford University’s Administrative Panel on Lab Animal Care (IACUC 25065). Four days after electroporation/transduction, different populations of live (DAPI-negative) targeted cells were sorted. Mock-treated cells were also sorted to control for the effect of the sorting procedure. Directly after sorting, cells were transplanted into one femur of sub-lethally irradiated mice (200 rad, 24 hr before transplant). Mice were randomly assigned to each experimental group and analyzed in a blinded fashion.</p></sec><sec id="s4-8"><title>Assessment of human engraftment</title><p>12 weeks after transplantation, mice were sacrificed, mouse bone marrow (BM) was harvested from the transplanted femur by flushing. Non-specific antibody binding was blocked (10% vol/vol, TruStain FcX, BioLegend) and cells were stained (30 min, 4°C, dark) with monoclonal anti-human HLA-ABC APC-Cy7 (W6/32, BioLegend), anti-mouse CD45.1 PE-Cy7 (A20, eBioScience, San Diego, CA, USA), CD19 APC (HIB19, BD511 Biosciences), CD33 PE (WM53, BD Biosciences), and anti-mouse mTer119 PE-Cy5 (TER-119, BD Biosciences) antibodies, and Propidium Iodide to detect dead cells. Human engraftment was defined as HLA-ABC<sup>+</sup> cells.</p></sec><sec id="s4-9"><title>Analysis of HBB-AAVS1 translocations</title><p>Genomic DNA was extracted from sorted populations using QuickExtract DNA Extraction Solution. For ddPCR quantification of translocations, ddPCR droplets were generated on a QX200 Droplet Generator (Bio-Rad) according to manufacturer’s protocol. Briefly, PCR reactions were set up in a 25 µL total volume per reaction with the ddPCR Supermix for Probes (No dUTP) (Bio-Rad). A HEX reference assay detecting copy number input of the <italic>TERT</italic> gene was used to normalize for genomic DNA input (Bio-Rad: saCP1000100). A custom assay designed to detect the translocations between <italic>HBB</italic> and <italic>AAVS1</italic> consisted of: Forward primer: 5’-TCAGGGCAGAGCCATCTATTGC-3’, Reverse primer: 5’-CCAGATAAGGAATCTGCCTAACAGG-3', 5'−6FAM/ZEN/3'-IBFQ-labeled Probe (IDT): 5’-CTTCTGACACAACTGTGTTCACTAGCAACC-3’. The translocation assay was used at a final concentration of 900 nM for each of the primers and a final concentration of 250 nM for the probe. 20 µL of the PCR reaction was used for droplet generation, and 40 µL of the droplets was used in the following PCR conditions: 95° - 10 min, 50 cycles of 94° - 30 s, 57°C – 30 s, and 72° - 2 min, finalize with 98° - 10 min and 4°C until droplet analysis. Droplets were analyzed on a QX200 Droplet Reader (Bio-Rad) detecting FAM and HEX positive droplets. Control samples with non-template control (H<sub>2</sub>O) or genomic DNA from mock-electroporated samples were included in the entire process. Translocation frequencies were calculated as the translocation copy number per µL divided by the TERT copy number per µL. For sequencing of translocations, PCR products were generated using Phusion polymerase (Fisher Scientific) with the forward and reverse primers listed above for the translocation ddPCR assay. PCR amplicons were gel-purified and cloned into the pMiniT 2.0 plasmid using the NEB PCR Cloning Kit (NEB) according to manufacturer’s recommendations. Ligated plasmid reactions were transformed into XL-1 Blue competent cells, plated on ampicillin-containing agar plates, and single colonies were sequenced by MCLAB (South San Francisco, CA, USA) using rolling circle amplification followed by sequencing using the following primer: 5’-ACCTGCCAACCAAAGCGAGAAC-3’.</p></sec><sec id="s4-10"><title>Analysis of cell viability and proliferation</title><p>Modified cells were FACS-sorted into individual wells of a 96-well U bottom plate and expanded in HSPC retention media (see above) at a density of &lt;100,000 cells per mL. To check viability and proliferation after multiplexed HR, cells from a single well were recovered and a known number of absolute counting beads (CountBright beads, Invitrogen) was added. Cells were stained with Ghost Dye Red 780 (Tonbo Biosciences) for 30 min at 4°C in the dark and analyzed on a FACS-Aria II without further manipulation to reduce potential cells loss. Viable cells were determined as GhostDye Red 780 negative and exact cell counts were assessed through concomitant acquisition of 10,000 beads. Cell counts were calculated based on ratio of beads to cells within the suspension.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>ROB was supported through an Individual Postdoctoral grant (DFF–1333-00106B) and a Sapere Aude, Research Talent grant (DFF–1331-00735B) both from the Danish Council for Independent Research, Medical Sciences. DPD was supported through the Stanford Child Health Research Institute (CHRI) Grant and Postdoctoral Award. AR was supported by an Erwin Schroedinger Fellowship from the Austrian Research Council (FWF). MHP gratefully acknowledges the support of the Amon Carter Foundation, the Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research and NIH grant support R01-AI097320, and R01-AI120766. RM gratefully acknowledges the support of the Stanford Ludwig Center for Cancer Stem Cell Research, the Stanford Child Health Research Institute (CHRI), and NIH grant support R01-CA188055. RM is a New York Stem Cell Foundation Robertson Investigator and Leukemia and Lymphoma Society Scholar. We thank David Russell (University of Washington) for the pDGM6 plasmid, the Binn’s Program for Cord Blood Research (Stanford University) for cord blood-derived CD34<sup>+</sup> HSPCs, Sruthi Mantri (Stanford University) for isolation of CD34<sup>+</sup> HSPCs from cord blood, and Carmencita Nicolas for help with in vivo experiments. We also thank members of the Porteus and Majeti labs, for helpful input, comments and discussion.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Ravindra Majeti has equity and consults for Forty Seven Inc.</p></fn><fn fn-type="COI-statement" id="conf3"><p>Matthew Porteus has equity and consults for CRISPR Therapeutics.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocol was approved by Stanford University's Administrative Panel on Lab Animal Care (IACUC 25065).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.27873.020</object-id><label>Supplementary file 1.</label><caption><title>(a) Overview of Cas9 and rAAV6 mono-genic targeting experiments performed in cord blood (CB), bone marrow (BM), and mobilized peripheral blood (mPB)-derived human CD34<sup>+</sup>HSPCs.</title><p>This table summarizes all independent experiments targeting <italic>HBB</italic>, <italic>CCR5</italic>, <italic>IL2RG</italic>, <italic>RUNX1</italic>, <italic>ASXL1</italic>, <italic>STAG2</italic>, and <italic>AAVS1</italic> in HSPCs and the reporter genes used. GFP: green fluorescent protein, tNGFR: truncated Nerve Growth Factor Receptor, BFP: blue fluorescent protein. Efficiencies were averaged across 47 independent experiments, <italic>N</italic> = 47. (b) Overview of genotypes for the non-integrated alleles in mono-genic integration experiments. The three tables show the different INDELs that were identified by Sanger Sequencing of the non-edited allele in mono-genic targeting experiments (<italic>CCR5</italic>, <italic>IL2RG</italic>, and <italic>RUNX1</italic>) used to analyze genotype frequencies shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b and d</xref>. Alleles are grouped into WT (blue), INDELs that preserve the reading frame (red) and INDELs that disrupt the reading frame (green). Note that INDELs that preserve the reading frame can potentially be disruptive depending on the size and location. For example, the 147 bp deletion in <italic>RUNX1</italic> is considered disruptive because of its large size and because it deletes the splice donor site in the intron between exon 2 and 3. For <italic>IL2RG</italic>, one clone was found to have an allele with integration of 230 bp from the donor (at the end of the RHA and 72 bp into the ITR). (c) Overview of di-genic and biallelic targeting experiments in cord blood (CB), bone marrow (BM), and mobilized peripheral blood (mPB)-derived human CD34<sup>+</sup>HSPCs. This table summarizes the experiments targeting HSPCs for biallelic and di-genic HR and the reporter genes used. GFP: green fluorescent protein, tNGFR: truncated Nerve Growth Factor Receptor, BFP: blue fluorescent protein. Efficiencies were averaged across 16 and 17 independent experiments, respectively, <italic>N</italic> = 16 and <italic>N</italic> = 17. (d) Overview of genotypes for the non-integrated alleles in clones with tri-genic integrations. Each row of the table represents the genotype of a colony established from a tri-genic targeting experiment (<italic>IL2RG</italic>, <italic>HBB</italic>, and <italic>CCR5</italic>). Alleles are grouped into WT (blue), INDELs that preserve the reading frame (red) and INDELs that disrupt the reading frame (green). Note that INDELs that preserve the reading frame can potentially be disruptive depending on the size and location. For <italic>HBB</italic> we identified one clone where <italic>HBD</italic> had been used as repair template and three clones with mono-allelic integration of part of the SFFV promoter indicative of HR events that ended prematurely. (e) Overview of tetra-allelic, tri-genic, and tetra-genic targeting experiments performed in human CD34<sup>+</sup>HSPCs derived from cord blood (CB), bone marrow (BM), and mobilized peripheral blood (mPB). This table summarizes the independent multiplexing HR experiments performed for tetra-allelic, tri-genic, and tetra-genic targeting and the reporter genes used. GFP: green fluorescent protein, tNGFR: truncated Nerve Growth Factor Receptor, BFP: blue fluorescent protein. Efficiencies were averaged across independent experiments, <italic>N</italic> = 3 (tetra-allelic and tetra-genic) and <italic>N</italic> = 6 (tri-genic).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-27873-supp1-v2.pptx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.27873.021</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-27873-transrepform-v2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurnhammer</surname> <given-names>C</given-names></name><name><surname>Haase</surname> <given-names>M</given-names></name><name><surname>Muether</surname> <given-names>N</given-names></name><name><surname>Hausl</surname> <given-names>M</given-names></name><name><surname>Rauschhuber</surname> <given-names>C</given-names></name><name><surname>Huber</surname> <given-names>I</given-names></name><name><surname>Nitschko</surname> <given-names>H</given-names></name><name><surname>Busch</surname> <given-names>U</given-names></name><name><surname>Sing</surname> <given-names>A</given-names></name><name><surname>Ehrhardt</surname> <given-names>A</given-names></name><name><surname>Baiker</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences</article-title><source>Human Gene Therapy Methods</source><volume>23</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2011.034</pub-id><pub-id pub-id-type="pmid">22428977</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bak</surname> <given-names>RO</given-names></name><name><surname>Porteus</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CRISPR-mediated integration of large gene cassettes using AAV donor vectors</article-title><source>Cell Reports</source><volume>20</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.064</pub-id><pub-id pub-id-type="pmid">28723575</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonini</surname> <given-names>C</given-names></name><name><surname>Grez</surname> <given-names>M</given-names></name><name><surname>Traversari</surname> <given-names>C</given-names></name><name><surname>Ciceri</surname> <given-names>F</given-names></name><name><surname>Marktel</surname> <given-names>S</given-names></name><name><surname>Ferrari</surname> <given-names>G</given-names></name><name><surname>Dinauer</surname> <given-names>M</given-names></name><name><surname>Sadat</surname> <given-names>M</given-names></name><name><surname>Aiuti</surname> <given-names>A</given-names></name><name><surname>Deola</surname> <given-names>S</given-names></name><name><surname>Radrizzani</surname> <given-names>M</given-names></name><name><surname>Hagenbeek</surname> <given-names>A</given-names></name><name><surname>Apperley</surname> <given-names>J</given-names></name><name><surname>Ebeling</surname> <given-names>S</given-names></name><name><surname>Martens</surname> <given-names>A</given-names></name><name><surname>Kolb</surname> <given-names>HJ</given-names></name><name><surname>Weber</surname> <given-names>M</given-names></name><name><surname>Lotti</surname> <given-names>F</given-names></name><name><surname>Grande</surname> <given-names>A</given-names></name><name><surname>Weissinger</surname> <given-names>E</given-names></name><name><surname>Bueren</surname> <given-names>JA</given-names></name><name><surname>Lamana</surname> <given-names>M</given-names></name><name><surname>Falkenburg</surname> <given-names>JH</given-names></name><name><surname>Heemskerk</surname> <given-names>MH</given-names></name><name><surname>Austin</surname> <given-names>T</given-names></name><name><surname>Kornblau</surname> <given-names>S</given-names></name><name><surname>Marini</surname> <given-names>F</given-names></name><name><surname>Benati</surname> <given-names>C</given-names></name><name><surname>Magnani</surname> <given-names>Z</given-names></name><name><surname>Cazzaniga</surname> <given-names>S</given-names></name><name><surname>Toma</surname> <given-names>S</given-names></name><name><surname>Gallo-Stampino</surname> <given-names>C</given-names></name><name><surname>Introna</surname> <given-names>M</given-names></name><name><surname>Slavin</surname> <given-names>S</given-names></name><name><surname>Greenberg</surname> <given-names>PD</given-names></name><name><surname>Bregni</surname> <given-names>M</given-names></name><name><surname>Mavilio</surname> <given-names>F</given-names></name><name><surname>Bordignon</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Safety of retroviral gene marking with a truncated NGF receptor</article-title><source>Nature Medicine</source><volume>9</volume><fpage>367</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/nm0403-367</pub-id><pub-id pub-id-type="pmid">12669036</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>A</given-names></name><name><surname>Woods</surname> <given-names>WS</given-names></name><name><surname>Perez-Pinera</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multiplexed targeted genome engineering using a universal nuclease-assisted vector integration system</article-title><source>ACS Synthetic Biology</source><volume>5</volume><fpage>582</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.6b00056</pub-id><pub-id pub-id-type="pmid">27159246</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bystrykh</surname> <given-names>L</given-names></name><name><surname>Weersing</surname> <given-names>E</given-names></name><name><surname>Dontje</surname> <given-names>B</given-names></name><name><surname>Sutton</surname> <given-names>S</given-names></name><name><surname>Pletcher</surname> <given-names>MT</given-names></name><name><surname>Wiltshire</surname> <given-names>T</given-names></name><name><surname>Su</surname> <given-names>AI</given-names></name><name><surname>Vellenga</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Manly</surname> <given-names>KF</given-names></name><name><surname>Lu</surname> <given-names>L</given-names></name><name><surname>Chesler</surname> <given-names>EJ</given-names></name><name><surname>Alberts</surname> <given-names>R</given-names></name><name><surname>Jansen</surname> <given-names>RC</given-names></name><name><surname>Williams</surname> <given-names>RW</given-names></name><name><surname>Cooke</surname> <given-names>MP</given-names></name><name><surname>de Haan</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'</article-title><source>Nature Genetics</source><volume>37</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/ng1497</pub-id><pub-id pub-id-type="pmid">15711547</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>SM</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Corces-Zimmerman</surname> <given-names>MR</given-names></name><name><surname>Xavy</surname> <given-names>S</given-names></name><name><surname>Rastogi</surname> <given-names>S</given-names></name><name><surname>Hong</surname> <given-names>WJ</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Medeiros</surname> <given-names>BC</given-names></name><name><surname>Tyvoll</surname> <given-names>DA</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia</article-title><source>Nature Medicine</source><volume>21</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/nm.3788</pub-id><pub-id pub-id-type="pmid">25599133</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Barretto</surname> <given-names>R</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname> <given-names>C</given-names></name><name><surname>Multani</surname> <given-names>P</given-names></name><name><surname>Robbins</surname> <given-names>D</given-names></name><name><surname>Kim</surname> <given-names>HT</given-names></name><name><surname>Le</surname> <given-names>T</given-names></name><name><surname>Hoggatt</surname> <given-names>J</given-names></name><name><surname>Pelus</surname> <given-names>LM</given-names></name><name><surname>Desponts</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>YB</given-names></name><name><surname>Rezner</surname> <given-names>B</given-names></name><name><surname>Armand</surname> <given-names>P</given-names></name><name><surname>Koreth</surname> <given-names>J</given-names></name><name><surname>Glotzbecker</surname> <given-names>B</given-names></name><name><surname>Ho</surname> <given-names>VT</given-names></name><name><surname>Alyea</surname> <given-names>E</given-names></name><name><surname>Isom</surname> <given-names>M</given-names></name><name><surname>Kao</surname> <given-names>G</given-names></name><name><surname>Armant</surname> <given-names>M</given-names></name><name><surname>Silberstein</surname> <given-names>L</given-names></name><name><surname>Hu</surname> <given-names>P</given-names></name><name><surname>Soiffer</surname> <given-names>RJ</given-names></name><name><surname>Scadden</surname> <given-names>DT</given-names></name><name><surname>Ritz</surname> <given-names>J</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>North</surname> <given-names>TE</given-names></name><name><surname>Mendlein</surname> <given-names>J</given-names></name><name><surname>Ballen</surname> <given-names>K</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Antin</surname> <given-names>JH</given-names></name><name><surname>Shoemaker</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation</article-title><source>Blood</source><volume>122</volume><fpage>3074</fpage><lpage>3081</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-05-503177</pub-id><pub-id pub-id-type="pmid">23996087</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lima</surname> <given-names>M</given-names></name><name><surname>McNiece</surname> <given-names>I</given-names></name><name><surname>Robinson</surname> <given-names>SN</given-names></name><name><surname>Munsell</surname> <given-names>M</given-names></name><name><surname>Eapen</surname> <given-names>M</given-names></name><name><surname>Horowitz</surname> <given-names>M</given-names></name><name><surname>Alousi</surname> <given-names>A</given-names></name><name><surname>Saliba</surname> <given-names>R</given-names></name><name><surname>McMannis</surname> <given-names>JD</given-names></name><name><surname>Kaur</surname> <given-names>I</given-names></name><name><surname>Kebriaei</surname> <given-names>P</given-names></name><name><surname>Parmar</surname> <given-names>S</given-names></name><name><surname>Popat</surname> <given-names>U</given-names></name><name><surname>Hosing</surname> <given-names>C</given-names></name><name><surname>Champlin</surname> <given-names>R</given-names></name><name><surname>Bollard</surname> <given-names>C</given-names></name><name><surname>Molldrem</surname> <given-names>JJ</given-names></name><name><surname>Jones</surname> <given-names>RB</given-names></name><name><surname>Nieto</surname> <given-names>Y</given-names></name><name><surname>Andersson</surname> <given-names>BS</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Oran</surname> <given-names>B</given-names></name><name><surname>Cooper</surname> <given-names>LJ</given-names></name><name><surname>Worth</surname> <given-names>L</given-names></name><name><surname>Qazilbash</surname> <given-names>MH</given-names></name><name><surname>Korbling</surname> <given-names>M</given-names></name><name><surname>Rondon</surname> <given-names>G</given-names></name><name><surname>Ciurea</surname> <given-names>S</given-names></name><name><surname>Bosque</surname> <given-names>D</given-names></name><name><surname>Maewal</surname> <given-names>I</given-names></name><name><surname>Simmons</surname> <given-names>PJ</given-names></name><name><surname>Shpall</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cord-blood engraftment with ex vivo mesenchymal-cell coculture</article-title><source>New England Journal of Medicine</source><volume>367</volume><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1207285</pub-id><pub-id pub-id-type="pmid">23234514</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Ravin</surname> <given-names>SS</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Choi</surname> <given-names>U</given-names></name><name><surname>Allen</surname> <given-names>C</given-names></name><name><surname>Koontz</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Theobald-Whiting</surname> <given-names>N</given-names></name><name><surname>Chu</surname> <given-names>J</given-names></name><name><surname>Garofalo</surname> <given-names>M</given-names></name><name><surname>Sweeney</surname> <given-names>C</given-names></name><name><surname>Kardava</surname> <given-names>L</given-names></name><name><surname>Moir</surname> <given-names>S</given-names></name><name><surname>Viley</surname> <given-names>A</given-names></name><name><surname>Natarajan</surname> <given-names>P</given-names></name><name><surname>Su</surname> <given-names>L</given-names></name><name><surname>Kuhns</surname> <given-names>D</given-names></name><name><surname>Zarember</surname> <given-names>KA</given-names></name><name><surname>Peshwa</surname> <given-names>MV</given-names></name><name><surname>Malech</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease</article-title><source>Science Translational Medicine</source><volume>9</volume><elocation-id>eaah3480</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aah3480</pub-id><pub-id pub-id-type="pmid">28077679</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dever</surname> <given-names>DP</given-names></name><name><surname>Bak</surname> <given-names>RO</given-names></name><name><surname>Reinisch</surname> <given-names>A</given-names></name><name><surname>Camarena</surname> <given-names>J</given-names></name><name><surname>Washington</surname> <given-names>G</given-names></name><name><surname>Nicolas</surname> <given-names>CE</given-names></name><name><surname>Pavel-Dinu</surname> <given-names>M</given-names></name><name><surname>Saxena</surname> <given-names>N</given-names></name><name><surname>Wilkens</surname> <given-names>AB</given-names></name><name><surname>Mantri</surname> <given-names>S</given-names></name><name><surname>Uchida</surname> <given-names>N</given-names></name><name><surname>Hendel</surname> <given-names>A</given-names></name><name><surname>Narla</surname> <given-names>A</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name><name><surname>Weinberg</surname> <given-names>KI</given-names></name><name><surname>Porteus</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells</article-title><source>Nature</source><volume>539</volume><fpage>384</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/nature20134</pub-id><pub-id pub-id-type="pmid">27820943</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeWitt</surname> <given-names>MA</given-names></name><name><surname>Magis</surname> <given-names>W</given-names></name><name><surname>Bray</surname> <given-names>NL</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Berman</surname> <given-names>JR</given-names></name><name><surname>Urbinati</surname> <given-names>F</given-names></name><name><surname>Heo</surname> <given-names>SJ</given-names></name><name><surname>Mitros</surname> <given-names>T</given-names></name><name><surname>Muñoz</surname> <given-names>DP</given-names></name><name><surname>Boffelli</surname> <given-names>D</given-names></name><name><surname>Kohn</surname> <given-names>DB</given-names></name><name><surname>Walters</surname> <given-names>MC</given-names></name><name><surname>Carroll</surname> <given-names>D</given-names></name><name><surname>Martin</surname> <given-names>DI</given-names></name><name><surname>Corn</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>360ra134</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf9336</pub-id><pub-id pub-id-type="pmid">27733558</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doulatov</surname> <given-names>S</given-names></name><name><surname>Notta</surname> <given-names>F</given-names></name><name><surname>Laurenti</surname> <given-names>E</given-names></name><name><surname>Dick</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hematopoiesis: a human perspective</article-title><source>Cell Stem Cell</source><volume>10</volume><fpage>120</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.01.006</pub-id><pub-id pub-id-type="pmid">22305562</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyquem</surname> <given-names>J</given-names></name><name><surname>Mansilla-Soto</surname> <given-names>J</given-names></name><name><surname>Giavridis</surname> <given-names>T</given-names></name><name><surname>van der Stegen</surname> <given-names>SJ</given-names></name><name><surname>Hamieh</surname> <given-names>M</given-names></name><name><surname>Cunanan</surname> <given-names>KM</given-names></name><name><surname>Odak</surname> <given-names>A</given-names></name><name><surname>Gönen</surname> <given-names>M</given-names></name><name><surname>Sadelain</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection</article-title><source>Nature</source><volume>543</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature21405</pub-id><pub-id pub-id-type="pmid">28225754</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fares</surname> <given-names>I</given-names></name><name><surname>Chagraoui</surname> <given-names>J</given-names></name><name><surname>Gareau</surname> <given-names>Y</given-names></name><name><surname>Gingras</surname> <given-names>S</given-names></name><name><surname>Ruel</surname> <given-names>R</given-names></name><name><surname>Mayotte</surname> <given-names>N</given-names></name><name><surname>Csaszar</surname> <given-names>E</given-names></name><name><surname>Knapp</surname> <given-names>DJ</given-names></name><name><surname>Miller</surname> <given-names>P</given-names></name><name><surname>Ngom</surname> <given-names>M</given-names></name><name><surname>Imren</surname> <given-names>S</given-names></name><name><surname>Roy</surname> <given-names>DC</given-names></name><name><surname>Watts</surname> <given-names>KL</given-names></name><name><surname>Kiem</surname> <given-names>HP</given-names></name><name><surname>Herrington</surname> <given-names>R</given-names></name><name><surname>Iscove</surname> <given-names>NN</given-names></name><name><surname>Humphries</surname> <given-names>RK</given-names></name><name><surname>Eaves</surname> <given-names>CJ</given-names></name><name><surname>Cohen</surname> <given-names>S</given-names></name><name><surname>Marinier</surname> <given-names>A</given-names></name><name><surname>Zandstra</surname> <given-names>PW</given-names></name><name><surname>Sauvageau</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal</article-title><source>Science</source><volume>345</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1126/science.1256337</pub-id><pub-id pub-id-type="pmid">25237102</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname> <given-names>P</given-names></name><name><surname>Schiroli</surname> <given-names>G</given-names></name><name><surname>Escobar</surname> <given-names>G</given-names></name><name><surname>Tomaso</surname> <given-names>TD</given-names></name><name><surname>Firrito</surname> <given-names>C</given-names></name><name><surname>Calabria</surname> <given-names>A</given-names></name><name><surname>Moi</surname> <given-names>D</given-names></name><name><surname>Mazzieri</surname> <given-names>R</given-names></name><name><surname>Bonini</surname> <given-names>C</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>van der Burg</surname> <given-names>M</given-names></name><name><surname>Gentner</surname> <given-names>B</given-names></name><name><surname>Montini</surname> <given-names>E</given-names></name><name><surname>Lombardo</surname> <given-names>A</given-names></name><name><surname>Naldini</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeted genome editing in human repopulating haematopoietic stem cells</article-title><source>Nature</source><volume>510</volume><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/nature13420</pub-id><pub-id pub-id-type="pmid">24870228</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckl</surname> <given-names>D</given-names></name><name><surname>Kowalczyk</surname> <given-names>MS</given-names></name><name><surname>Yudovich</surname> <given-names>D</given-names></name><name><surname>Belizaire</surname> <given-names>R</given-names></name><name><surname>Puram</surname> <given-names>RV</given-names></name><name><surname>McConkey</surname> <given-names>ME</given-names></name><name><surname>Thielke</surname> <given-names>A</given-names></name><name><surname>Aster</surname> <given-names>JC</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/nbt.2951</pub-id><pub-id pub-id-type="pmid">24952903</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendel</surname> <given-names>A</given-names></name><name><surname>Bak</surname> <given-names>RO</given-names></name><name><surname>Clark</surname> <given-names>JT</given-names></name><name><surname>Kennedy</surname> <given-names>AB</given-names></name><name><surname>Ryan</surname> <given-names>DE</given-names></name><name><surname>Roy</surname> <given-names>S</given-names></name><name><surname>Steinfeld</surname> <given-names>I</given-names></name><name><surname>Lunstad</surname> <given-names>BD</given-names></name><name><surname>Kaiser</surname> <given-names>RJ</given-names></name><name><surname>Wilkens</surname> <given-names>AB</given-names></name><name><surname>Bacchetta</surname> <given-names>R</given-names></name><name><surname>Tsalenko</surname> <given-names>A</given-names></name><name><surname>Dellinger</surname> <given-names>D</given-names></name><name><surname>Bruhn</surname> <given-names>L</given-names></name><name><surname>Porteus</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>985</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1038/nbt.3290</pub-id><pub-id pub-id-type="pmid">26121415</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoban</surname> <given-names>MD</given-names></name><name><surname>Lumaquin</surname> <given-names>D</given-names></name><name><surname>Kuo</surname> <given-names>CY</given-names></name><name><surname>Romero</surname> <given-names>Z</given-names></name><name><surname>Long</surname> <given-names>J</given-names></name><name><surname>Ho</surname> <given-names>M</given-names></name><name><surname>Young</surname> <given-names>CS</given-names></name><name><surname>Mojadidi</surname> <given-names>M</given-names></name><name><surname>Fitz-Gibbon</surname> <given-names>S</given-names></name><name><surname>Cooper</surname> <given-names>AR</given-names></name><name><surname>Lill</surname> <given-names>GR</given-names></name><name><surname>Urbinati</surname> <given-names>F</given-names></name><name><surname>Campo-Fernandez</surname> <given-names>B</given-names></name><name><surname>Bjurstrom</surname> <given-names>CF</given-names></name><name><surname>Pellegrini</surname> <given-names>M</given-names></name><name><surname>Hollis</surname> <given-names>RP</given-names></name><name><surname>Kohn</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells</article-title><source>Molecular Therapy</source><volume>24</volume><fpage>1561</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.148</pub-id><pub-id pub-id-type="pmid">27406980</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Friedman</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Taupin</surname> <given-names>V</given-names></name><name><surname>Crooks</surname> <given-names>GM</given-names></name><name><surname>Kohn</surname> <given-names>DB</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Cannon</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/nbt.1663</pub-id><pub-id pub-id-type="pmid">20601939</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname> <given-names>N</given-names></name><name><surname>Hagin</surname> <given-names>D</given-names></name><name><surname>Sommer</surname> <given-names>K</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name><name><surname>Khan</surname> <given-names>I</given-names></name><name><surname>Clough</surname> <given-names>C</given-names></name><name><surname>Ochs</surname> <given-names>HD</given-names></name><name><surname>Rawlings</surname> <given-names>DJ</given-names></name><name><surname>Scharenberg</surname> <given-names>AM</given-names></name><name><surname>Torgerson</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome</article-title><source>Blood</source><volume>127</volume><fpage>2513</fpage><lpage>2522</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-11-683235</pub-id><pub-id pub-id-type="pmid">26903548</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hultquist</surname> <given-names>JF</given-names></name><name><surname>Schumann</surname> <given-names>K</given-names></name><name><surname>Woo</surname> <given-names>JM</given-names></name><name><surname>Manganaro</surname> <given-names>L</given-names></name><name><surname>McGregor</surname> <given-names>MJ</given-names></name><name><surname>Doudna</surname> <given-names>J</given-names></name><name><surname>Simon</surname> <given-names>V</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>Marson</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells</article-title><source>Cell Reports</source><volume>17</volume><fpage>1438</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.080</pub-id><pub-id pub-id-type="pmid">27783955</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>IF</given-names></name><name><surname>Hirata</surname> <given-names>RK</given-names></name><name><surname>Russell</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>AAV-mediated gene targeting methods for human cells</article-title><source>Nature Protocols</source><volume>6</volume><fpage>482</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nprot.2011.301</pub-id><pub-id pub-id-type="pmid">21455185</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Cho</surname> <given-names>SW</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins</article-title><source>Genome Research</source><volume>24</volume><fpage>1012</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1101/gr.171322.113</pub-id><pub-id pub-id-type="pmid">24696461</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotin</surname> <given-names>RM</given-names></name><name><surname>Linden</surname> <given-names>RM</given-names></name><name><surname>Berns</surname> <given-names>KI</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination</article-title><source>The EMBO journal</source><volume>11</volume><fpage>5071</fpage><lpage>5078</lpage><pub-id pub-id-type="pmid">1334463</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Staahl</surname> <given-names>BT</given-names></name><name><surname>Alla</surname> <given-names>RK</given-names></name><name><surname>Doudna</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery</article-title><source>eLife</source><volume>3</volume><elocation-id>e04766</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.04766</pub-id><pub-id pub-id-type="pmid">25497837</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddalo</surname> <given-names>D</given-names></name><name><surname>Manchado</surname> <given-names>E</given-names></name><name><surname>Concepcion</surname> <given-names>CP</given-names></name><name><surname>Bonetti</surname> <given-names>C</given-names></name><name><surname>Vidigal</surname> <given-names>JA</given-names></name><name><surname>Han</surname> <given-names>YC</given-names></name><name><surname>Ogrodowski</surname> <given-names>P</given-names></name><name><surname>Crippa</surname> <given-names>A</given-names></name><name><surname>Rekhtman</surname> <given-names>N</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name><name><surname>Ventura</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system</article-title><source>Nature</source><volume>516</volume><fpage>423</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1038/nature13902</pub-id><pub-id pub-id-type="pmid">25337876</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeti</surname> <given-names>R</given-names></name><name><surname>Park</surname> <given-names>CY</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood</article-title><source>Cell Stem Cell</source><volume>1</volume><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.10.001</pub-id><pub-id pub-id-type="pmid">18371405</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname> <given-names>PK</given-names></name><name><surname>Ferreira</surname> <given-names>LM</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Meissner</surname> <given-names>TB</given-names></name><name><surname>Boutwell</surname> <given-names>CL</given-names></name><name><surname>Friesen</surname> <given-names>M</given-names></name><name><surname>Vrbanac</surname> <given-names>V</given-names></name><name><surname>Garrison</surname> <given-names>BS</given-names></name><name><surname>Stortchevoi</surname> <given-names>A</given-names></name><name><surname>Bryder</surname> <given-names>D</given-names></name><name><surname>Musunuru</surname> <given-names>K</given-names></name><name><surname>Brand</surname> <given-names>H</given-names></name><name><surname>Tager</surname> <given-names>AM</given-names></name><name><surname>Allen</surname> <given-names>TM</given-names></name><name><surname>Talkowski</surname> <given-names>ME</given-names></name><name><surname>Rossi</surname> <given-names>DJ</given-names></name><name><surname>Cowan</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.10.004</pub-id><pub-id pub-id-type="pmid">25517468</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazumdar</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Xavy</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Reinisch</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Flynn</surname> <given-names>RA</given-names></name><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Chan</surname> <given-names>SM</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Koenig</surname> <given-names>JL</given-names></name><name><surname>Hong</surname> <given-names>WJ</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation</article-title><source>Cell Stem Cell</source><volume>17</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.09.017</pub-id><pub-id pub-id-type="pmid">26607380</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>DG</given-names></name><name><surname>Petek</surname> <given-names>LM</given-names></name><name><surname>Russell</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Adeno-associated virus vectors integrate at chromosome breakage sites</article-title><source>Nature Genetics</source><volume>36</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1038/ng1380</pub-id><pub-id pub-id-type="pmid">15208627</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullenders</surname> <given-names>J</given-names></name><name><surname>Aranda-Orgilles</surname> <given-names>B</given-names></name><name><surname>Lhoumaud</surname> <given-names>P</given-names></name><name><surname>Keller</surname> <given-names>M</given-names></name><name><surname>Pae</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Kayembe</surname> <given-names>C</given-names></name><name><surname>Rocha</surname> <given-names>PP</given-names></name><name><surname>Raviram</surname> <given-names>R</given-names></name><name><surname>Gong</surname> <given-names>Y</given-names></name><name><surname>Premsrirut</surname> <given-names>PK</given-names></name><name><surname>Tsirigos</surname> <given-names>A</given-names></name><name><surname>Bonneau</surname> <given-names>R</given-names></name><name><surname>Skok</surname> <given-names>JA</given-names></name><name><surname>Cimmino</surname> <given-names>L</given-names></name><name><surname>Hoehn</surname> <given-names>D</given-names></name><name><surname>Aifantis</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>1833</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1084/jem.20151323</pub-id><pub-id pub-id-type="pmid">26438359</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naldini</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gene therapy returns to centre stage</article-title><source>Nature</source><volume>526</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nature15818</pub-id><pub-id pub-id-type="pmid">26469046</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>JP</given-names></name><name><surname>Gönen</surname> <given-names>M</given-names></name><name><surname>Figueroa</surname> <given-names>ME</given-names></name><name><surname>Fernandez</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Racevskis</surname> <given-names>J</given-names></name><name><surname>Van Vlierberghe</surname> <given-names>P</given-names></name><name><surname>Dolgalev</surname> <given-names>I</given-names></name><name><surname>Thomas</surname> <given-names>S</given-names></name><name><surname>Aminova</surname> <given-names>O</given-names></name><name><surname>Huberman</surname> <given-names>K</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Viale</surname> <given-names>A</given-names></name><name><surname>Socci</surname> <given-names>ND</given-names></name><name><surname>Heguy</surname> <given-names>A</given-names></name><name><surname>Cherry</surname> <given-names>A</given-names></name><name><surname>Vance</surname> <given-names>G</given-names></name><name><surname>Higgins</surname> <given-names>RR</given-names></name><name><surname>Ketterling</surname> <given-names>RP</given-names></name><name><surname>Gallagher</surname> <given-names>RE</given-names></name><name><surname>Litzow</surname> <given-names>M</given-names></name><name><surname>van den Brink</surname> <given-names>MR</given-names></name><name><surname>Lazarus</surname> <given-names>HM</given-names></name><name><surname>Rowe</surname> <given-names>JM</given-names></name><name><surname>Luger</surname> <given-names>S</given-names></name><name><surname>Ferrando</surname> <given-names>A</given-names></name><name><surname>Paietta</surname> <given-names>E</given-names></name><name><surname>Tallman</surname> <given-names>MS</given-names></name><name><surname>Melnick</surname> <given-names>A</given-names></name><name><surname>Abdel-Wahab</surname> <given-names>O</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia</article-title><source>New England Journal of Medicine</source><volume>366</volume><fpage>1079</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112304</pub-id><pub-id pub-id-type="pmid">22417203</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname> <given-names>RJ</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Yim</surname> <given-names>MJ</given-names></name><name><surname>Swiech</surname> <given-names>L</given-names></name><name><surname>Kempton</surname> <given-names>HR</given-names></name><name><surname>Dahlman</surname> <given-names>JE</given-names></name><name><surname>Parnas</surname> <given-names>O</given-names></name><name><surname>Eisenhaure</surname> <given-names>TM</given-names></name><name><surname>Jovanovic</surname> <given-names>M</given-names></name><name><surname>Graham</surname> <given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname> <given-names>S</given-names></name><name><surname>Heidenreich</surname> <given-names>M</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Langer</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>DG</given-names></name><name><surname>Hacohen</surname> <given-names>N</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Feng</surname> <given-names>G</given-names></name><name><surname>Sharp</surname> <given-names>PA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-Cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirot</surname> <given-names>L</given-names></name><name><surname>Philip</surname> <given-names>B</given-names></name><name><surname>Schiffer-Mannioui</surname> <given-names>C</given-names></name><name><surname>Le Clerre</surname> <given-names>D</given-names></name><name><surname>Chion-Sotinel</surname> <given-names>I</given-names></name><name><surname>Derniame</surname> <given-names>S</given-names></name><name><surname>Potrel</surname> <given-names>P</given-names></name><name><surname>Bas</surname> <given-names>C</given-names></name><name><surname>Lemaire</surname> <given-names>L</given-names></name><name><surname>Galetto</surname> <given-names>R</given-names></name><name><surname>Lebuhotel</surname> <given-names>C</given-names></name><name><surname>Eyquem</surname> <given-names>J</given-names></name><name><surname>Cheung</surname> <given-names>GW</given-names></name><name><surname>Duclert</surname> <given-names>A</given-names></name><name><surname>Gouble</surname> <given-names>A</given-names></name><name><surname>Arnould</surname> <given-names>S</given-names></name><name><surname>Peggs</surname> <given-names>K</given-names></name><name><surname>Pule</surname> <given-names>M</given-names></name><name><surname>Scharenberg</surname> <given-names>AM</given-names></name><name><surname>Smith</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multiplex genome-edited T-cell manufacturing platform for &quot;Off-the-Shelf&quot; adoptive T-cell immunotherapies</article-title><source>Cancer Research</source><volume>75</volume><fpage>3853</fpage><lpage>3864</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3321</pub-id><pub-id pub-id-type="pmid">26183927</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popat</surname> <given-names>U</given-names></name><name><surname>Mehta</surname> <given-names>RS</given-names></name><name><surname>Rezvani</surname> <given-names>K</given-names></name><name><surname>Fox</surname> <given-names>P</given-names></name><name><surname>Kondo</surname> <given-names>K</given-names></name><name><surname>Marin</surname> <given-names>D</given-names></name><name><surname>McNiece</surname> <given-names>I</given-names></name><name><surname>Oran</surname> <given-names>B</given-names></name><name><surname>Hosing</surname> <given-names>C</given-names></name><name><surname>Olson</surname> <given-names>A</given-names></name><name><surname>Parmar</surname> <given-names>S</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Andreeff</surname> <given-names>M</given-names></name><name><surname>Kebriaei</surname> <given-names>P</given-names></name><name><surname>Kaur</surname> <given-names>I</given-names></name><name><surname>Yvon</surname> <given-names>E</given-names></name><name><surname>de Lima</surname> <given-names>M</given-names></name><name><surname>Cooper</surname> <given-names>LJ</given-names></name><name><surname>Tewari</surname> <given-names>P</given-names></name><name><surname>Champlin</surname> <given-names>RE</given-names></name><name><surname>Nieto</surname> <given-names>Y</given-names></name><name><surname>Andersson</surname> <given-names>BS</given-names></name><name><surname>Alousi</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>RB</given-names></name><name><surname>Qazilbash</surname> <given-names>MH</given-names></name><name><surname>Bashir</surname> <given-names>Q</given-names></name><name><surname>Ciurea</surname> <given-names>S</given-names></name><name><surname>Ahmed</surname> <given-names>S</given-names></name><name><surname>Anderlini</surname> <given-names>P</given-names></name><name><surname>Bosque</surname> <given-names>D</given-names></name><name><surname>Bollard</surname> <given-names>C</given-names></name><name><surname>Molldrem</surname> <given-names>JJ</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Rondon</surname> <given-names>G</given-names></name><name><surname>Thomas</surname> <given-names>M</given-names></name><name><surname>Miller</surname> <given-names>L</given-names></name><name><surname>Wolpe</surname> <given-names>S</given-names></name><name><surname>Simmons</surname> <given-names>P</given-names></name><name><surname>Robinson</surname> <given-names>S</given-names></name><name><surname>Zweidler-McKay</surname> <given-names>PA</given-names></name><name><surname>Shpall</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation</article-title><source>Blood</source><volume>125</volume><fpage>2885</fpage><lpage>2892</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-01-607366</pub-id><pub-id pub-id-type="pmid">25778529</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinisch</surname> <given-names>A</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Gratzinger</surname> <given-names>D</given-names></name><name><surname>Hong</surname> <given-names>WJ</given-names></name><name><surname>Schallmoser</surname> <given-names>K</given-names></name><name><surname>Strunk</surname> <given-names>D</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells</article-title><source>Nature Medicine</source><volume>22</volume><fpage>812</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/nm.4103</pub-id><pub-id pub-id-type="pmid">27213817</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saydaminova</surname> <given-names>K</given-names></name><name><surname>Ye</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Richter</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>N</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name><name><surname>Papapetrou</surname> <given-names>E</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>Palmer</surname> <given-names>D</given-names></name><name><surname>Ng</surname> <given-names>P</given-names></name><name><surname>Ehrhardt</surname> <given-names>A</given-names></name><name><surname>Lieber</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation</article-title><source>Molecular Therapy - Methods &amp; Clinical Development</source><volume>1</volume><elocation-id>14057</elocation-id><pub-id pub-id-type="doi">10.1038/mtm.2014.57</pub-id><pub-id pub-id-type="pmid">26052525</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Boyer</surname> <given-names>E</given-names></name><name><surname>Simeonov</surname> <given-names>DR</given-names></name><name><surname>Subramaniam</surname> <given-names>M</given-names></name><name><surname>Gate</surname> <given-names>RE</given-names></name><name><surname>Haliburton</surname> <given-names>GE</given-names></name><name><surname>Ye</surname> <given-names>CJ</given-names></name><name><surname>Bluestone</surname> <given-names>JA</given-names></name><name><surname>Doudna</surname> <given-names>JA</given-names></name><name><surname>Marson</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Generation of knock-in primary human T cells using Cas9 ribonucleoproteins</article-title><source>PNAS</source><volume>112</volume><fpage>10437</fpage><lpage>10442</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512503112</pub-id><pub-id pub-id-type="pmid">26216948</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seita</surname> <given-names>J</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hematopoietic stem cell: self-renewal versus differentiation</article-title><source>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</source><volume>2</volume><fpage>640</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1002/wsbm.86</pub-id><pub-id pub-id-type="pmid">20890962</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Milazzo</surname> <given-names>JP</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Kinney</surname> <given-names>JB</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>661</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/nbt.3235</pub-id><pub-id pub-id-type="pmid">25961408</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname> <given-names>CL</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Choi</surname> <given-names>U</given-names></name><name><surname>Merling</surname> <given-names>RK</given-names></name><name><surname>Liu</surname> <given-names>A</given-names></name><name><surname>Bodansky</surname> <given-names>A</given-names></name><name><surname>Burkett</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>JW</given-names></name><name><surname>De Ravin</surname> <given-names>SS</given-names></name><name><surname>Malech</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction</article-title><source>Molecular Therapy</source><volume>25</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2016.11.012</pub-id><pub-id pub-id-type="pmid">28153086</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebas</surname> <given-names>P</given-names></name><name><surname>Stein</surname> <given-names>D</given-names></name><name><surname>Tang</surname> <given-names>WW</given-names></name><name><surname>Frank</surname> <given-names>I</given-names></name><name><surname>Wang</surname> <given-names>SQ</given-names></name><name><surname>Lee</surname> <given-names>G</given-names></name><name><surname>Spratt</surname> <given-names>SK</given-names></name><name><surname>Surosky</surname> <given-names>RT</given-names></name><name><surname>Giedlin</surname> <given-names>MA</given-names></name><name><surname>Nichol</surname> <given-names>G</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>Ando</surname> <given-names>DG</given-names></name><name><surname>Kalos</surname> <given-names>M</given-names></name><name><surname>Collman</surname> <given-names>RG</given-names></name><name><surname>Binder-Scholl</surname> <given-names>G</given-names></name><name><surname>Plesa</surname> <given-names>G</given-names></name><name><surname>Hwang</surname> <given-names>WT</given-names></name><name><surname>Levine</surname> <given-names>BL</given-names></name><name><surname>June</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV</article-title><source>New England Journal of Medicine</source><volume>370</volume><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1300662</pub-id><pub-id pub-id-type="pmid">24597865</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viny</surname> <given-names>AD</given-names></name><name><surname>Ott</surname> <given-names>CJ</given-names></name><name><surname>Spitzer</surname> <given-names>B</given-names></name><name><surname>Rivas</surname> <given-names>M</given-names></name><name><surname>Meydan</surname> <given-names>C</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Yelin</surname> <given-names>D</given-names></name><name><surname>Shank</surname> <given-names>K</given-names></name><name><surname>Reyes</surname> <given-names>J</given-names></name><name><surname>Chiu</surname> <given-names>A</given-names></name><name><surname>Romin</surname> <given-names>Y</given-names></name><name><surname>Boyko</surname> <given-names>V</given-names></name><name><surname>Thota</surname> <given-names>S</given-names></name><name><surname>Maciejewski</surname> <given-names>JP</given-names></name><name><surname>Melnick</surname> <given-names>A</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>1819</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1084/jem.20151317</pub-id><pub-id pub-id-type="pmid">26438361</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voit</surname> <given-names>RA</given-names></name><name><surname>Hendel</surname> <given-names>A</given-names></name><name><surname>Pruett-Miller</surname> <given-names>SM</given-names></name><name><surname>Porteus</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nuclease-mediated gene editing by homologous recombination of the human globin locus</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>1365</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt947</pub-id><pub-id pub-id-type="pmid">24157834</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voit</surname> <given-names>RA</given-names></name><name><surname>McMahon</surname> <given-names>MA</given-names></name><name><surname>Sawyer</surname> <given-names>SL</given-names></name><name><surname>Porteus</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Generation of an HIV resistant T-cell line by targeted &quot;stacking&quot; of restriction factors</article-title><source>Molecular Therapy</source><volume>21</volume><fpage>786</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.284</pub-id><pub-id pub-id-type="pmid">23358186</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Exline</surname> <given-names>CM</given-names></name><name><surname>DeClercq</surname> <given-names>JJ</given-names></name><name><surname>Llewellyn</surname> <given-names>GN</given-names></name><name><surname>Hayward</surname> <given-names>SB</given-names></name><name><surname>Li</surname> <given-names>PW</given-names></name><name><surname>Shivak</surname> <given-names>DA</given-names></name><name><surname>Surosky</surname> <given-names>RT</given-names></name><name><surname>Gregory</surname> <given-names>PD</given-names></name><name><surname>Holmes</surname> <given-names>MC</given-names></name><name><surname>Cannon</surname> <given-names>PM</given-names></name><name><surname>Pw</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>1256</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1038/nbt.3408</pub-id><pub-id pub-id-type="pmid">26551060</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname> <given-names>NB</given-names></name><name><surname>Bottero</surname> <given-names>V</given-names></name><name><surname>Schmidt</surname> <given-names>M</given-names></name><name><surname>von Kalle</surname> <given-names>C</given-names></name><name><surname>Verma</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gene therapy: therapeutic gene causing lymphoma</article-title><source>Nature</source><volume>440</volume><elocation-id>1123</elocation-id><pub-id pub-id-type="doi">10.1038/4401123a</pub-id><pub-id pub-id-type="pmid">16641981</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Diaz-Flores</surname> <given-names>E</given-names></name><name><surname>Lintault</surname> <given-names>L</given-names></name><name><surname>Kogan</surname> <given-names>SC</given-names></name><name><surname>Shannon</surname> <given-names>K</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1389</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1101/gad.1940710</pub-id><pub-id pub-id-type="pmid">20595231</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.27873.024</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Levine</surname><given-names>Ross L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Multiplexed Genetic Engineering of Hematopoietic Stem and Progenitor Cells using CRISPR and AAV6&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, one of whom, Ross L Levine (Reviewer #1), is a member of our Board of Reviewing Editors.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Although all three reviewers found merit in this work, some specific issues were raised which resonated with all of the reviewers and which need to be addressed. One is the relatively low level of engraftment, which is more striking than with the mock controls, raising concerns as to whether the multiplex gene editing is toxic to cells. This is an important question which needs to be thoughtfully addressed. The other major concern relates to potential off-target effects, and the need to see additional genomic data which addresses this question more comprehensively. Third, the authors should discuss how their method can be applied to biologic studies and what are the novel strengths and limitations to their approach.</p><p><italic>Reviewer #1:</italic> </p><p>The authors describe a novel genome editing tool using HR mediated genome editing by combining delivery of Cas9/sgRNA complexes by electrocorporation and delivery of the homologous donor DNA and reporter genes by transduction of cells with a recombinant adeno associated vector.</p><p>They use this technology to introduce different modifications such as monoallelic and biallelic modification of a particular gene, but also simultaneous targeting of 4 different genes in human HSPCs – which might have important applications for functional and therapeutic studies in hematological diseases.</p><p>The paper does push the envelope further by showing additional technical improvements, which are substantive, above and beyond other reports. However, little biological insight is provided and it would be helpful to show novel biology to make this report of wide interest to the field. Nonetheless, as a Tools and Resources submission, this condition is relaxed a bit as long as the technique provides a rigorous proof of principle.</p><p>1) Analysis of clones derived from single cell methylcellulose assays harboring monoallelic integration showed gene specific differences in the modification of non-integrated alleles. What do the authors think was the cause of these gene specific differences? And how could these be influenced?</p><p>2) For the biallelic targeted integration in HPSCs, why was the rate of double positivity different in cells that have received RNP+AAV targeting e.g. Runx1 (14%) vs. CCR5 (1.2%)? Is this due to a lower transduction efficiency for the CCR5? Or other mechanisms interfering with HR? And how could this be optimized for CCR5? In <xref ref-type="fig" rid="fig1">Figure 1E</xref>, the authors should include the data for RUNX1, HBB and CCR5 as well.</p><p>3) How did the authors design the sgRNA for introducing biallelic modifications? Were sgRNA on the both strands &quot;reciprocal&quot;? or were the sgRNA on both strands located at different nucleotide sequences?</p><p>4) For the transplantation studies, 15 weeks after sorting double positive cells and transplanting them into sublethally irradiated mice, mice were sacrificed in engraftment (CDHLA-ABC+/CD45+) was assessed. After 15 weeks 1.5% of cells showed engraftment. Do the authors have sequential data, how this population changes over time – increases/ decreases?</p><p>5) When multigenic HR was performed, was there evidence of NHEJ besides the HR directed repair? And what was its frequency? Was there evidence of gene fusions/ translocations?</p><p>6) Cell viability 3 days post targeting 3 genes (RNP+AAV) was &lt;70% compared to 100% in AAV only cells. Since the fraction of triple pos. cells is low (e.g. Runx1/HBB/ASXL1 2.9%), was flow analysis repeated at a later time point to ensure the triple-positive cells were still alive?</p><p>7) The authors postulate that multiplex genome editing using their method will enable and facilitate functional studies of gene networks. Nevertheless, simultaneous gene editing of 3 genes showed an efficiency of 2.6% and of 4 genes and efficiency of 1% only. These fractions seem very small. Particularly in the setting of in vivo studies such as a BMT experiment: the authors were able to transplant ~30 000 double positive cells modifying 2 genes simultaneously with a double pos. rate of 10.2.% (di genic approach). If the triple or quadruple positive rate drops to 1%, this would mean to transplant 3 000 cells for a BMT, which seems very low. Please comment on this.</p><p><italic>Reviewer #2:</italic> </p><p>This is a nicely designed and executed study using CRISPR tools to introduce reporter genes in human CD34+ HSPCs allowing sorting and/or tracking of cells with inactivation of specific genes.</p><p>The authors present an elegant approach that would be useful to model disease relevant inactivating mutations in human HSPCs, and potentially also point mutations (the authors discuss how this might be possible by modifying the CRISPR tools they present but do not actually show data on these strategies).</p><p>The data are of high quality, well presented and clearly described. A minor criticism is that the results are presented in a repetitive and a bit monotonous style, but nevertheless clear and with enough detail for others to reproduce.</p><p>1) <xref ref-type="fig" rid="fig2">Figure 2E</xref> shows low engraftment (in the 0.1-1% range) of the edited cells compared to mock, indicating a potential engraftment impairment (although the mouse numbers are low). Can the authors comment on this?</p><p>2) Related to my comment above, the authors could discuss a bit more the potential limitations of their approach. For example, an important point to discuss is the time it would take from the beginning of culture to cell sorting and how this might impact HSPC function.</p><p>3) Trypan blue and Annexin staining (Figure 1—figure supplement 3 and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>) may not be adequate ways to assess toxicity, as dead cells may be continuously removed from the cultures and not detected with these methods. I think that cell counts depicting the expansion of the edited cells vs. mock or unmodified would be more convincing way to evaluate toxicity of the method.</p><p>4) <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>: the number of untargeted IL2RG alleles without indels is much higher than that of untargeted alleles of CCR5 or other genes. Is this due to lower gRNA activity (reflected by overall lower targeting efficiency in the IL2RG locus?) Can the authors comment on this?</p><p><italic>Reviewer #3:</italic> </p><p>In this manuscript, Bak et al. describes a method to perform multiplex homology-directed genome editing of human HSPCs. Using Cas9-sgRNA ribonucleoprotein complex and rAAV as a donor for the homology-directed repair template, they remarkably achieve up to four (potentially more) HDR genome editing events, with little if any modification to a published protocol. Some weaknesses include lack of rigorous assessment of potential negative effects of multiplexed editing on HSPCs function and the genetic consequences. The work also lacks evidence that the functional consequences of multiplex genome editing can be read out even with the potential negative effects the editing protocol may have. Overall, this work could potentially be a highly valuable technique for the hematology field upon clarifying these issues.</p><p>1) The chimerism achieved after transplantation of dual-edited cells are substantially lower than mock edited cells with no indication as to whether the cells had multi-lineage reconstitution, raising a concern that the multiplexed editing impaired the function of HSPCs. At least the contribution of dual-edited cells to each hematopoietic lineage should be shown. A concern is that this method uses rAAV6 at a high MOI (50,000-100,000 per gene. With tetra-editing, cells are exposed to 200,000 units of AAV). Is this high level of AAV exposure impairing the reconstitution potential of HSPCs (inflammation response or immune reaction?)? Do cells electroporated with Cas9-sgRNA RNP but not exposed to AAV reconstitute better?</p><p>2) The authors should analyze the off-target mutagenesis events. There seems to be a substantial fraction of cells that undergo random integration of rAAV6 reporter, perhaps due to the high MOI of rAAV6 used. For example, <xref ref-type="fig" rid="fig1">Figure 1A</xref> shows that 7-8% of cells become reporter<sup>low</sup>, some of which are maintained for long term (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) indicating that the template DNA integrated into the HSPC genome. I agree that sorting reporter<sup>high</sup> cells will enrich for cells with HDR editing, but for a technology driven study it will be important to elucidate the nature of these reporter<sup>low</sup> cells. This will be particularly important for some cell like T-cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) that somehow have lower expression of the reporter genes. It also suggests that a fraction of reporter<sup>high</sup> cells also have substantial non-targeted integration, which may affect their function. Are these cells enriched for randomly integrated cells, or do they have specific integration into specific loci? Are these cells diluting the episome (so that the frequency of reporter<sup>low</sup> cells decreases in <xref ref-type="fig" rid="fig1">Figure 1B</xref>) or these cells dying due to the mutagenic events of random integration?</p><p>3) There is little effort to demonstrate the precision of the HDR events other than the &quot;in-out PCR&quot;, which only tells that the reporter was integrated into the correct loci but does not tell whether the HDR was precise, or whether off-target cutting occurred, or whether translocation occurred at a level that impedes the usefulness of this protocol. The first point is important given that the authors envision their method could be used for targeted SNP knock-in. Off-targeting editing due to the use of multiple sgRNA is cautioned in the discussion but no data provided to assess whether this is a significant concern or not. The authors should perform sequencing analyses to provide quantitative assessment of precise vs. imprecise HDR editing at the targeted loci, and the extent to which off-target editing/translocation occurs.</p><p>4) Although I understand that this is a method paper describing a toolbox to edit the genomes of HSPCs in a multiplexed manner, it is difficult to fully appreciate the potential of this method without a real example of how this could be used. In another word, there is no proof that it is possible to assess the functional consequences of multiplex editing other than analyzing the expression of reporter genes. Any of the concerns raised above (1-3) can impede the potential of multiplex HSPC editing. Can the authors provide evidence that multiplex editing can be used to examine the combinatorial effects of gene editing?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.27873.025</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Although all three reviewers found merit in this work, some specific issues were raised which resonated with all of the reviewers and which need to be addressed. One is the relatively low level of engraftment, which is more striking than with the mock controls, raising concerns as to whether the multiplex gene editing is toxic to cells. This is an important question which needs to be thoughtfully addressed. The other major concern relates to potential off-target effects, and the need to see additional genomic data which addresses this question more comprehensively. Third, the authors should discuss how their method can be applied to biologic studies and what are the novel strengths and limitations to their approach.</p><p>Reviewer #1: […] The paper does push the envelope further by showing additional technical improvements, which are substantive, above and beyond other reports. However, little biological insight is provided and it would be helpful to show novel biology to make this report of wide interest to the field. Nonetheless, as a Tools and Resources submission, this condition is relaxed a bit as long as the technique provides a rigorous proof of principle.</p></disp-quote><p>We thank the reviewer for the supportive words. In the revised manuscript, we now provide an example of how the enrichment technology may be used. We now show that knockout of the cohesin complex member <italic>STAG2</italic> significantly decreases erythroid colony formation in human CD34<sup>+</sup> HSPCs (new <xref ref-type="fig" rid="fig1">Figure 1D</xref>). Since the sgRNA used to manipulate <italic>STAG2</italic> has moderate efficiency (compared to other genes presented in our manuscript), the magnitude of the observed erythroid differentiation deficit in knockout cells could only be observed because our presented methodology allowed for the purification of modified cells. This further emphasizes the potential of our presented technology. Knockdown strategies using “INDEL-based” CRISPR/Cas9 approaches without the ability to purify modified cells would most likely miss such an important phenotype.</p><disp-quote content-type="editor-comment"><p>1) Analysis of clones derived from single cell methylcellulose assays harboring monoallelic integration showed gene specific differences in the modification of non-integrated alleles. What do the authors think was the cause of these gene specific differences? And how could these be influenced?</p></disp-quote><p>We believe that the differences observed in the modification of the non-integrated allele in clones with mono-allelic integration could be due to differences in the accessibility of the chromatin, which was recently examined in Chen et al., Nature Comm. 2017, Apr 7;8:14958. This could influence the efficiencies of the individual sgRNAs and dynamics of INDELs vs. HR.</p><disp-quote content-type="editor-comment"><p>2) For the biallelic targeted integration in HPSCs, why was the rate of double positivity different in cells that have received RNP+AAV targeting e.g. Runx1 (14%) vs. CCR5 (1.2%)? Is this due to a lower transduction efficiency for the CCR5? Or other mechanisms interfering with HR? And how could this be optimized for CCR5? In <xref ref-type="fig" rid="fig1">Figure 1E</xref>, the authors should include the data for RUNX1, HBB and CCR5 as well.</p></disp-quote><p>We have observed that <italic>CCR5</italic> targeting rates, both mono and bi-allelic, are generally lower than at other loci and believe this may be a sgRNA-specific effect that changes the dynamics and spectrum of INDEL creation which may impact HR frequencies. The lack of CCR5 biallelic targeting is also corroborated in <xref ref-type="fig" rid="fig1">Figure 1C</xref> where we analyzed allelic frequencies in methylcellulose colonies. Increasing biallelic targeting at CCR5 may be achieved using a different sgRNA, increasing Cas9 concentrations and/or increasing the amount of AAV6 used. However, we believe that optimizing bi-allelic integration into the <italic>CCR5</italic> gene, while interesting from the perspective of generating an HIV-resistant immune system, goes beyond the scope of the work here. As for the data for <xref ref-type="fig" rid="fig1">Figure 1E</xref>, we have only performed this experiment for <italic>HBB</italic>.</p><disp-quote content-type="editor-comment"><p>3) How did the authors design the sgRNA for introducing biallelic modifications? Were sgRNA on the both strands &quot;reciprocal&quot;? or were the sgRNA on both strands located at different nucleotide sequences?</p></disp-quote><p>For each targeted gene, only one sgRNA is used. This sgRNA targets the same target sites on the two alleles. We have made textual changes to clarify this. Thus, it is important to target sequences that are not polymorphic in the human population when using a single sgRNA and trying to create bi-allelic modifications.</p><disp-quote content-type="editor-comment"><p>4) For the transplantation studies, 15 weeks after sorting double positive cells and transplanting them into sublethally irradiated mice, mice were sacrificed in engraftment (CDHLA-ABC+/CD45+) was assessed. After 15 weeks 1.5% of cells showed engraftment. Do the authors have sequential data, how this population changes over time – increases/ decreases?</p></disp-quote><p>We have now extended the transplantation experiment and show new data in <xref ref-type="fig" rid="fig3">Figure 3f</xref>, <xref ref-type="fig" rid="fig3">Figure 3g</xref>, and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>. These transplants were performed intra-femorally and at end point upon euthanasia, engraftment was assessed in the transplanted femur. To allow robust assessment of engraftment efficiencies, we did not perform serial aspirates from the transplanted femur. The suggestion to examine engraftment over time is an excellent point, and future studies using significantly larger numbers of mice focused on the engraftment kinetics of genome edited cells will be necessary to investigate this point.</p><disp-quote content-type="editor-comment"><p>5) When multigenic HR was performed, was there evidence of NHEJ besides the HR directed repair? And what was its frequency? Was there evidence of gene fusions/ translocations?</p></disp-quote><p>If the reviewer refers to NHEJ-mediated capture of the AAV donor at on or off target sites, those are events that we have observed. This data is presented in <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref> where we mix-match nucleases and donors. The frequencies are below 10% of the total targeting frequencies (i.e. 1 out of every 10 targeted cells may have a capture). If the reviewer refers to NHEJ on non-targeted alleles, we have included that data for tri-genic targeting in Supplementary file 4. These data show that 85% of the clones with tri-genic integrations were modified on all alleles either by biallelic integration or INDELs on the non-integrated allele that were mostly disruptive. As suggested by the reviewer, we have now included data quantifying translocations when targeting two genes simultaneously. As expected, we do observe translocations, although at low frequencies (around 0.3%) for a monocentric translocation, which has been reported to be the most frequent translocation type (Poirot et al., Cancer Res. 2015). This new data is presented in <xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</p><disp-quote content-type="editor-comment"><p>6) Cell viability 3 days post targeting 3 genes (RNP+AAV) was &lt;70% compared to 100% in AAV only cells. Since the fraction of triple pos. cells is low (e.g. Runx1/HBB/ASXL1 2.9%), was flow analysis repeated at a later time point to ensure the triple-positive cells were still alive?</p></disp-quote><p>We show survival as well as proliferation of cells targeted with multiplexed HR at time points beyond 4 days post electroporation in methylcellulose and liquid culture experiments. See for example <xref ref-type="fig" rid="fig1">Figure 1B, 1C</xref>, <xref ref-type="fig" rid="fig2">2B, C</xref>, <xref ref-type="fig" rid="fig3">3B, C, D</xref>, and 3E. Though this data is not comparative, the CFU assay in <xref ref-type="fig" rid="fig4">Figure 4B</xref> compares total colony formation of sorted reporter triple-positive cells to cells only transduced with AAV. Finally, long-term survival of modified cells is confirmed in the transplantation data displayed in <xref ref-type="fig" rid="fig3">Figure 3F and 3G</xref>.</p><p>To further underscore this point, we have performed viability as well as a cell proliferation assay over a one-week culture period after sorting di-genically targeted cells (day of sort in this specific experiment is defined as Day 0 even though it is actually day 4 after editing), which confirms viability and proliferation capacity of targeted cells equivalent to non-targeted or mock-treated controls. We have added this data from a single cord blood donor to <xref ref-type="fig" rid="respfig1">Author response image 1</xref>.</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.27873.023</object-id><label>Author response image 1.</label><caption/><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-27873-resp-fig1-v2"/></fig><disp-quote content-type="editor-comment"><p>7) The authors postulate that multiplex genome editing using their method will enable and facilitate functional studies of gene networks. Nevertheless, simultaneous gene editing of 3 genes showed an efficiency of 2.6% and of 4 genes and efficiency of 1% only. These fractions seem very small. Particularly in the setting of in vivo studies such as a BMT experiment: the authors were able to transplant ~30 000 double positive cells modifying 2 genes simultaneously with a double pos. rate of 10.2.% (di genic approach). If the triple or quadruple positive rate drops to 1%, this would mean to transplant 3 000 cells for a BMT, which seems very low. Please comment on this.</p></disp-quote><p>The reviewer brings up an excellent consideration. We have now included a revised transplantation experiment using higher numbers of cells with di-genic targeted integration (new <xref ref-type="fig" rid="fig3">Figure 3F and 3G</xref>). This data includes a mouse with human chimerism of 19.4%. However, we do agree with the reviewer on this important point and have made textual changes to mention ways to overcome this challenge, such as starting with higher cell doses, expansion of modified cells, or transplantation into human bone ossicles, which require very few transplanted cells (Reinisch et al., Nature Med. 2016 Jul;22(<xref ref-type="bibr" rid="bib39">7</xref>):812-21.). While we believe that we have offered a multiplexing platform to build around, future studies will be needed to address these issues. In addition, while 1% can seem like a small percentage, human leukemias develop from a single cell and yet end up taking over the hematopoietic system. In collaborative work published with the Cleary lab, for example, leukemias developed after transplantation into NSG mice with very low genome editing frequencies (perhaps as low as 0.1%) (Buechele et al., Blood 2015). In those studies, only a single editing event was created (but in a powerful oncogene (MLL)), and the current approach allows the generation of multiple editing events in genes that might have weaker transformative effects than the MLL-AF9 fusion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…] The data are of high quality, well presented and clearly described. A minor criticism is that the results are presented in a repetitive and a bit monotonous style, but nevertheless clear and with enough detail for others to reproduce.</p></disp-quote><p>We appreciate the reviewer’s high praise of our study, as we also believe that it will advance the field for modeling hematological malignancies. We are sorry that we have erred on being monotonous in our presentation, but we felt it was more appropriate to attempt to give a balanced view rather than to overstate our data. In fact, we are tremendously excited about the data and both of our labs have fully embraced the discoveries and approach for studies of leukemogenesis and for developing novel cell based therapeutics.</p><disp-quote content-type="editor-comment"><p>1) <xref ref-type="fig" rid="fig2">Figure 2E</xref> shows low engraftment (in the 0.1-1% range) of the edited cells compared to mock, indicating a potential engraftment impairment (although the mouse numbers are low). Can the authors comment on this?</p></disp-quote><p>We have previously described that HSCs are more refractory to HR compared to short-lived hematopoietic progenitors (Dever and Bak et al., Nature 2016). Therefore, higher numbers of modified cells must be transplanted to achieve engraftment frequencies similar to that of unmodified cells. Since we are targeting multiple genes rather than just one, it is not surprising that within a population of cells purified based on HR-mediated marker expression the number of true HSCs is relatively low and that long-term engraftment consequently will be low. To show that higher engraftment is possible by using more cells, we have now updated the transplantation results with data from a new experiment transplanting higher cell numbers (new <xref ref-type="fig" rid="fig3">Figure 3F-G</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). For one mouse transplanted with enriched di-genically targeted cells we observed 19.4% multilineage chimerism showing that the limiting factor is HSC cell number within the targeted population. While we believe that we have provided enough evidence that multiplexed targeting occurs in HSPCs with long-term and multilineage potential, further studies are necessary to address the caveats of achieving high targeting rates in the most immature HSC compartment with subsequent high engraftment of multiplexed-HSPCs. We have also made text revisions with suggestions on how to overcome low engraftment (higher cell dose, pre-transplant in vitro expansion, and the use of a human bone ossicle transplantation model).</p><disp-quote content-type="editor-comment"><p>2) Related to my comment above, the authors could discuss a bit more the potential limitations of their approach. For example, an important point to discuss is the time it would take from the beginning of culture to cell sorting and how this might impact HSPC function.</p></disp-quote><p>We completely agree with the reviewer and have added this relevant information to the second paragraph of the Discussion.</p><disp-quote content-type="editor-comment"><p>3) Trypan blue and Annexin staining (Figure 1—figure supplement 3 and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>) may not be adequate ways to assess toxicity, as dead cells may be continuously removed from the cultures and not detected with these methods. I think that cell counts depicting the expansion of the edited cells vs. mock or unmodified would be more convincing way to evaluate toxicity of the method.</p></disp-quote><p>We agree with the reviewer. Expansion of edited cells is shown in the CFU assay in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, which compares the total colony formation of sorted reporter triple-positive cells to cells only transduced with AAV.</p><p>However, to further support this finding we have performed a cell proliferation assay as suggested by the reviewer using cell counts over a one-week culture period after sorting di-genically targeted cells. This assay confirms viability and proliferation capacity of targeted cells comparable to non-targeted or mock-treated controls. We have added this data from a single cord blood donor to <xref ref-type="fig" rid="respfig2">Author response image 2</xref> (day of sort is Day 0).</p><fig id="respfig2"><object-id pub-id-type="doi">10.7554/eLife.27873.024</object-id><label>Author response image 2.</label><caption/><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-27873-resp-fig2-v2"/></fig><disp-quote content-type="editor-comment"><p>4) <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>: the number of untargeted IL2RG alleles without indels is much higher than that of untargeted alleles of CCR5 or other genes. Is this due to lower gRNA activity (reflected by overall lower targeting efficiency in the IL2RG locus?) Can the authors comment on this?</p></disp-quote><p>As the reviewer suggests, this difference in INDEL frequency is likely gRNA and locus specific, and generally must be determined empirically. The <italic>CCR5</italic> guide used in this study creates a very high percentage of INDELs, specifically with a 1bp insertion (Bak and Porteus, Cell Reports, 2017), compared to the <italic>IL2RG</italic> sgRNA.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>In this manuscript, Bak et al. describes a method to perform multiplex homology-directed genome editing of human HSPCs. Using Cas9-sgRNA ribonucleoprotein complex and rAAV as a donor for the homology-directed repair template, they remarkably achieve up to four (potentially more) HDR genome editing events, with little if any modification to a published protocol. Some weaknesses include lack of rigorous assessment of potential negative effects of multiplexed editing on HSPCs function and the genetic consequences. The work also lacks evidence that the functional consequences of multiplex genome editing can be read out even with the potential negative effects the editing protocol may have. Overall, this work could potentially be a highly valuable technique for the hematology field upon clarifying these issues.</p></disp-quote><p>We very much appreciate the reviewer acknowledging that it is remarkable to achieve HR at 4 genes simultaneously and that this work could be a highly valuable technique for the hematology field. We have addressed the reviewer’s concerns below.</p><disp-quote content-type="editor-comment"><p>1) The chimerism achieved after transplantation of dual-edited cells are substantially lower than mock edited cells with no indication as to whether the cells had multi-lineage reconstitution, raising a concern that the multiplexed editing impaired the function of HSPCs. At least the contribution of dual-edited cells to each hematopoietic lineage should be shown. A concern is that this method uses rAAV6 at a high MOI (50,000-100,000 per gene. With tetra-editing, cells are exposed to 200,000 units of AAV). Is this high level of AAV exposure impairing the reconstitution potential of HSPCs (inflammation response or immune reaction?)? Do cells electroporated with Cas9-sgRNA RNP but not exposed to AAV reconstitute better?</p></disp-quote><p>We appreciate the reviewer’s concerns and agree that maintaining HSPC function is of highest importance for this methodology to be useful. We note that in the revised manuscript we have now updated the engraftment data with a new experiment transplanting more cells (new <xref ref-type="fig" rid="fig3">Figure 3F-G</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Notably, we can now report a mouse transplanted with di-genically targeted cells that displays 19.4% chimerism and multilineage reconstitution (B cells and myeloid cells). However, we agree that the engraftment capacity of HSPCs edited at multiple loci might be a concern. Lower engraftment of edited and enriched cells compared to unedited cells is something we have observed before (Dever &amp; Bak et al., Nature 2016). This phenomenon is caused by lower targeting rates in HSCs with long-term repopulation capacity (LT-HSCs). Therefore, an edited population contains less LT-HSCs than a non-edited, and it is therefore expected to observe less engraftment with edited populations. With that said, we are currently investigating expansion protocols, injection of a higher numbers of cells, and transplantation into a human bone ossicle xenograft model, but believe those studies are beyond the scope of this manuscript. We do not believe high levels of AAV exposure is influencing HSPC function, as we see equivalent number of progenitor-derived colonies compared to controls (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><disp-quote content-type="editor-comment"><p>2) The authors should analyze the off-target mutagenesis events. There seems to be a substantial fraction of cells that undergo random integration of rAAV6 reporter, perhaps due to the high MOI of rAAV6 used. For example, <xref ref-type="fig" rid="fig1">Figure 1A</xref> shows that 7-8% of cells become reporter<sup>low</sup>, some of which are maintained for long term (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) indicating that the template DNA integrated into the HSPC genome. I agree that sorting reporter<sup>high</sup> cells will enrich for cells with HDR editing, but for a technology driven study it will be important to elucidate the nature of these reporter<sup>low</sup> cells. This will be particularly important for some cell like T-cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) that somehow have lower expression of the reporter genes. It also suggests that a fraction of reporter<sup>high</sup> cells also have substantial non-targeted integration, which may affect their function. Are these cells enriched for randomly integrated cells, or do they have specific integration into specific loci? Are these cells diluting the episome (so that the frequency of reporter<sup>low</sup> cells decreases in <xref ref-type="fig" rid="fig1">Figure 1B</xref>) or these cells dying due to the mutagenic events of random integration?</p></disp-quote><p>The reviewer brings up an excellent point. The reporter<sup>low</sup> cells contain mostly cells that are not targeted, but also some cells that are targeted (based on consistent reporter expression over time as shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>). We have now included data that presents a more in-depth analysis of the reporter<sup>low</sup> fraction (new <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This data shows that most of the reporter<sup>low</sup> cells are diluting the episome and becoming negative over time, but some remain positive and even become reporter<sup>high</sup> because they are in fact targeted. The intensity of the reporter strongly correlates with the propensity to shift to reporter<sup>high</sup> expression either due to delayed HR or delayed expression. The T cells shown in <xref ref-type="fig" rid="fig2">Figure 2D</xref> have low expression because in this particular experiment a weaker promoter (EF1α promoter which is weaker than SFFV) drives the genes encoding fluorescent proteins. We know from our previous studies (Dever &amp; Bak et al., Nature 2016) that the reporter<sup>high</sup> monogenic targeted HSPCs can engraft long-term in secondary transplants, so it is unlikely that most of the reporter<sup>high</sup> cells have impaired function and more likely that they have specific integration into the on-target loci (as based on our genotyping data in colonies after 14 days in culture).</p><p>While we believe that off-target effects should always be considered when evaluating the results of a genome editing experiment, since we studied 8 different genes in this work to establish a proof of concept, we do not believe that a comprehensive analysis of potential off-target INDELs is within the scope of this manuscript. We did, however, add data on translocation frequencies (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>) to give readers a sense of the relative frequency of such events (rare, accounting for &lt;0.3%). Finally, we are not aware of any study using genome editing in which an off-target INDEL has confounded a biologic finding (in striking contrast to the RNAi methodology) and remain encouraged for the use of this approach. Nonetheless, we agree that unplanned genomic changes (from the Cas9/gRNA, from the AAV, and from simply culturing cells ex vivo) should always be carefully considered when interpreting the phenotypic effect of a genome editing experiment.</p><disp-quote content-type="editor-comment"><p>3) There is little effort to demonstrate the precision of the HDR events other than the &quot;in-out PCR&quot;, which only tells that the reporter was integrated into the correct loci but does not tell whether the HDR was precise, or whether off-target cutting occurred, or whether translocation occurred at a level that impedes the usefulness of this protocol. The first point is important given that the authors envision their method could be used for targeted SNP knock-in. Off-targeting editing due to the use of multiple sgRNA is cautioned in the discussion but no data provided to assess whether this is a significant concern or not. The authors should perform sequencing analyses to provide quantitative assessment of precise vs. imprecise HDR editing at the targeted loci, and the extent to which off-target editing/translocation occurs.</p></disp-quote><p>We appreciate the reviewer’s concerns. We and others have previously confirmed that the majority of HR events are perfect/seamless (for example Sather et al., STM, 2015; Dever &amp; Bak et al., Nature, 2016; Bak and Porteus, Cell Reports, 2017). We believe that a full off-target integration analysis is beyond the scope of this study, but as suggested by the reviewer, we have now included data quantifying translocations when targeting two genes simultaneously in HSPCs (new <xref ref-type="fig" rid="fig3">Figure 3E</xref>). As expected we do observe translocations, although at low frequencies (around 0.3%) for a monocentric translocation, which has been reported to be the most frequent translocation type.</p><disp-quote content-type="editor-comment"><p>4) Although I understand that this is a method paper describing a toolbox to edit the genomes of HSPCs in a multiplexed manner, it is difficult to fully appreciate the potential of this method without a real example of how this could be used. In another word, there is no proof that it is possible to assess the functional consequences of multiplex editing other than analyzing the expression of reporter genes. Any of the concerns raised above (1-3) can impede the potential of multiplex HSPC editing. Can the authors provide evidence that multiplex editing can be used to examine the combinatorial effects of gene editing?</p></disp-quote><p>We developed this method to be able to study genes involved in hematopoiesis that eliminates the need for random integration of lentiviral vectors to reduce gene expression in HSPCs. To exemplify the applicability of studying HSPC biology using targeted integration of a reporter gene combined with the enrichment methodology, we have now included new data (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) showing that knockout of the cohesion member gene <italic>STAG2</italic> leads to a drastic loss of erythroid colony formation. This highlights that sorting HR-targeted HSPCs can be used to study gene function.</p></body></sub-article></article>